{"ticker": {"uuid": "d35c590d-0934-414b-8dd9-361ee4d8852a", "symbol": "AUPH", "name": "Aurinia Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Consensus Recommendation of \"Hold\" from Brokerages", "summary": "Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has received a consensus \"Hold\" rating from six brokerages, with an average 12-month price target of $17.67. This comes despite its CEO and other insiders acquiring a significant number of shares recently. The company beat EPS estimates but missed revenue forecasts in its latest quarterly report.", "url": "https://www.marketbeat.com/instant-alerts/aurinia-pharmaceuticals-inc-nasdaqauph-receives-consensus-recommendation-of-hold-from-brokerages-2026-08-09", "source_link": "https://www.marketbeat.com/instant-alerts/aurinia-pharmaceuticals-inc-nasdaqauph-receives-consensus-recommendation-of-hold-from-brokerages-2026-08-09", "source_link_is_lookup": false, "source_name": "MarketBeat", "published_at": "2026-08-09T19:40:36", "published_display": "09 Aug 2026 19:40", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "positive", "sentiment_pct": 66, "tone_signals": ["Beat expectations"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.059143, "evidence_share": 6.6, "evidence_share_display": "6.6", "freshness_pct": 37.0, "age_days": 4.3, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences", "Earnings", "Financial Markets"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharmaceuticals (NASDAQ:AUPH) Downgraded by Wall Street Zen to Buy", "summary": "Wall Street Zen downgraded Aurinia Pharmaceuticals (NASDAQ:AUPH) from \"strong buy\" to \"buy\" due to revenue falling short of expectations, despite beating EPS estimates. The broader analyst consensus remains \"hold\" with an average price target of $17.67. Insider buying, including a significant purchase by the CEO, indicates confidence in the company, with insiders owning 10.4% of the stock.", "url": "https://www.marketbeat.com/instant-alerts/aurinia-pharmaceuticals-nasdaqauph-downgraded-by-wall-street-zen-to-buy-2026-08-08", "source_link": "https://www.marketbeat.com/instant-alerts/aurinia-pharmaceuticals-nasdaqauph-downgraded-by-wall-street-zen-to-buy-2026-08-08", "source_link_is_lookup": false, "source_name": "MarketBeat", "published_at": "2026-08-08T05:40:00", "published_display": "08 Aug 2026 05:40", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "positive", "sentiment_pct": 66, "tone_signals": ["Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.086856, "evidence_share": 9.6, "evidence_share_display": "9.6", "freshness_pct": 44.2, "age_days": 5.9, "influence_label": "Medium", "duplicate_count": 1, "topics": ["Earnings", "Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharmaceuticals Inc. 2026: Revenue $83.22M, EPS $0.28\u2014 10-Q Summary", "summary": "Aurinia Pharmaceuticals Inc. reported its 2026 quarterly results, with revenue reaching $83.22M and diluted EPS of $0.28, marking significant increases compared to the previous year. The growth was attributed to higher product sales, improved operating performance, and increased market penetration of LUPKYNIS. The company also highlighted clinical advancements, pipeline expansion, and enhanced manufacturing capacity.", "url": "https://www.tradingview.com/news/tradingview:b02ebfe2663ee:0-aurinia-pharmaceuticals-inc-2026-revenue-83-22m-eps-0-28-10-q-summary", "source_link": "https://www.tradingview.com/news/tradingview:b02ebfe2663ee:0-aurinia-pharmaceuticals-inc-2026-revenue-83-22m-eps-0-28-10-q-summary", "source_link_is_lookup": false, "source_name": "TradingView", "published_at": "2026-08-06T23:41:36", "published_display": "06 Aug 2026 23:41", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "positive", "sentiment_pct": 80, "tone_signals": ["Improving financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.119418, "evidence_share": 13.3, "evidence_share_display": "13.3", "freshness_pct": 37.2, "age_days": 7.1, "influence_label": "Medium", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharmaceuticals (AUPH) Earnings Date and Reports 2026", "summary": "Aurinia Pharmaceuticals (AUPH) announced its Q2 2026 earnings, reporting an EPS of $0.28, surpassing the consensus estimate of $0.24. However, quarterly revenue of $58.57 million fell short of analysts' expectations. The company also provided FY 2026 revenue guidance of $315.0 million-$325.0 million, slightly below the consensus estimate.", "url": "https://www.marketbeat.com/stocks/NASDAQ/AUPH/earnings", "source_link": "https://www.marketbeat.com/stocks/NASDAQ/AUPH/earnings", "source_link_is_lookup": false, "source_name": "MarketBeat", "published_at": "2026-08-06T23:41:36", "published_display": "06 Aug 2026 23:41", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 16, "tone_signals": ["Missed expectations", "Operating deterioration"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.129519, "evidence_share": 14.4, "evidence_share_display": "14.4", "freshness_pct": 37.2, "age_days": 7.1, "influence_label": "Medium", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences", "Financial Markets"], "evidence_basis": "archived_article", "score_included": true}, {"title": "How Investors Are Reacting To Aurinia Pharmaceuticals (AUPH) Strong Q2 Earnings And Reaffirmed 2026 Guidance", "summary": "Aurinia Pharmaceuticals reported strong Q2 2026 results with increased revenue and net income, alongside reaffirming its 2026 revenue guidance. This performance reinforces the company's near-term outlook for its LUPKYNIS drug, despite ongoing concerns about its reliance on a single product and future pipeline development. The article discusses how these results impact the investment narrative, highlighting both the company's current profitability and potential long-term risks.", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/how-investors-are-reacting-to-aurinia-pharmaceuticals-auph-s/amp", "source_link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/how-investors-are-reacting-to-aurinia-pharmaceuticals-auph-s/amp", "source_link_is_lookup": false, "source_name": "Simply Wall St", "published_at": "2026-08-06T21:11:18", "published_display": "06 Aug 2026 21:11", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 52, "tone_signals": ["Going Concern", "Improving financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.048425, "evidence_share": 5.4, "evidence_share_display": "5.4", "freshness_pct": 36.6, "age_days": 7.2, "influence_label": "Low", "duplicate_count": 2, "topics": ["Earnings", "Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress", "summary": "Aurinia Pharmaceuticals announced strong financial results for the three and six months ended June 30, 2026, with significant increases in total revenue, net product sales, and net income compared to the previous year. The company also reiterated its 2026 revenue guidance and provided updates on its clinical development programs, including the initiation of the PRESERVE study for LUPKYNIS and further clinical development of aritinercept for autoimmune diseases.", "url": "https://www.biospace.com/press-releases/aurinia-pharmaceuticals-reports-financial-results-for-the-three-and-six-months-ended-june-30-2026-and-provides-update-on-recent-business-progress", "source_link": "https://www.biospace.com/press-releases/aurinia-pharmaceuticals-reports-financial-results-for-the-three-and-six-months-ended-june-30-2026-and-provides-update-on-recent-business-progress", "source_link_is_lookup": false, "source_name": "BioSpace", "published_at": "2026-08-06T18:11:18", "published_display": "06 Aug 2026 18:11", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.047914, "evidence_share": 5.3, "evidence_share_display": "5.3", "freshness_pct": 36.0, "age_days": 7.4, "influence_label": "Low", "duplicate_count": 2, "topics": ["Earnings", "Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Earnings Flash (AUPH) Aurinia Pharmaceuticals Inc. Reports Q2 Revenue $83.2M, Vs. FactSet Est of $80.4M", "summary": "Aurinia Pharmaceuticals Inc. (AUPH) reported Q2 revenue of $83.2 million, surpassing the FactSet estimate of $80.4 million. The article also briefly mentions Unity Software's Q4 earnings, which showed a 35% year-over-year revenue increase to $609 million, exceeding the consensus estimate, despite a quarterly loss of 66 cents per share.", "url": "https://www.moomoo.com/news/post/74242756/earnings-flash-auph-aurinia-pharmaceuticals-inc-reports-q2-revenue-83", "source_link": "https://www.moomoo.com/news/post/74242756/earnings-flash-auph-aurinia-pharmaceuticals-inc-reports-q2-revenue-83", "source_link_is_lookup": false, "source_name": "Moomoo", "published_at": "2026-08-06T16:40:03", "published_display": "06 Aug 2026 16:40", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 55, "tone_signals": ["Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.048219, "evidence_share": 5.4, "evidence_share_display": "5.4", "freshness_pct": 35.7, "age_days": 7.4, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharmaceuticals posts Q2 revenue $83.2M, net income $37.4M; reiterates 2026 guidance", "summary": "Aurinia Pharmaceuticals announced its Q2 2026 financial results, reporting $83.2 million in revenue and $37.4 million in net income. The company also reiterated its full-year 2026 revenue guidance of $315 million to $325 million. Key highlights include strong sales for LUPKYNIS and advancements in clinical development programs.", "url": "https://www.tradingview.com/news/tradingview:69458a1583f25:0-aurinia-pharmaceuticals-posts-q2-revenue-83-2m-net-income-37-4m-reiterates-2026-guidance", "source_link": "https://www.tradingview.com/news/tradingview:69458a1583f25:0-aurinia-pharmaceuticals-posts-q2-revenue-83-2m-net-income-37-4m-reiterates-2026-guidance", "source_link_is_lookup": false, "source_name": "TradingView", "published_at": "2026-08-06T13:10:38", "published_display": "06 Aug 2026 13:10", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "positive", "sentiment_pct": 66, "tone_signals": ["Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.068743, "evidence_share": 7.6, "evidence_share_display": "7.6", "freshness_pct": 35.0, "age_days": 7.6, "influence_label": "Medium", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "AUPH: Strong revenue and net income growth driven by LUPKYNIS, with robust 2026 outlook", "summary": "Aurinia Pharmaceuticals (AUPH) reported strong double-digit year-over-year growth in revenue and net income, primarily due to LUPKYNIS sales and improved margins. The company's 2026 guidance anticipates continued growth in revenue and product sales. Additionally, new clinical programs and share repurchases indicate ongoing positive business momentum for AUPH.", "url": "https://www.tradingview.com/news/urn:summary_document_report:quartr.com:3976831:0", "source_link": "https://www.tradingview.com/news/urn:summary_document_report:quartr.com:3976831:0", "source_link_is_lookup": false, "source_name": "TradingView", "published_at": "2026-08-06T12:11:18", "published_display": "06 Aug 2026 12:11", "source_kind": "publisher", "company_focus": 0.86, "company_focus_pct": 86, "company_focus_label": "Company discussed", "sentiment": "positive", "sentiment_pct": 80, "tone_signals": ["Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.087201, "evidence_share": 9.7, "evidence_share_display": "9.7", "freshness_pct": 34.8, "age_days": 7.6, "influence_label": "Medium", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Targets Myasthenia Gravis With New Aritinercept Trial, Expanding Its Growth Story", "summary": "Aurinia Pharmaceuticals (AUPH) is expanding its clinical pipeline with a new Phase 1/2 trial for aritinercept, targeting generalized myasthenia gravis. The double-blind, placebo-controlled study will investigate the safety and efficacy of the dual BAFF/APRIL inhibitor in improving muscle weakness in this chronic autoimmune condition. This move diversifies Aurinia's portfolio beyond kidney disease into neurology, potentially supporting a higher valuation if early data are promising.", "url": "https://www.theglobeandmail.com/investing/markets/stocks/AUPH-Q/pressreleases/3641494/aurinia-targets-myasthenia-gravis-with-new-aritinercept-trial-expanding-its-growth-story", "source_link": "https://www.theglobeandmail.com/investing/markets/stocks/AUPH-Q/pressreleases/3641494/aurinia-targets-myasthenia-gravis-with-new-aritinercept-trial-expanding-its-growth-story", "source_link_is_lookup": false, "source_name": "The Globe and Mail", "published_at": "2026-08-05T00:04:51", "published_display": "05 Aug 2026 00:04", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.002641, "evidence_share": 0.3, "evidence_share_display": "0.3", "freshness_pct": 4.2, "age_days": 9.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "(AUPH) Movement as an Input in Quant Signal Sets", "summary": "Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is showing weak near and mid-term sentiment, challenging a positive long-term outlook, with support currently being tested. The article provides AI-generated trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. It highlights a significant 42.0:1 risk-reward setup targeting an 11.4% gain versus a 0.3% risk.", "url": "https://news.stocktradersdaily.com/news_release/14/AUPH_Movement_as_an_Input_in_Quant_Signal_Sets_080426013602_1785864962.html", "source_link": "https://news.stocktradersdaily.com/news_release/14/AUPH_Movement_as_an_Input_in_Quant_Signal_Sets_080426013602_1785864962.html", "source_link_is_lookup": false, "source_name": "Stock Traders Daily", "published_at": "2026-08-04T13:36:00", "published_display": "04 Aug 2026 13:36", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 55, "tone_signals": ["Positive financial language"], "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.053872, "evidence_share": 6.0, "evidence_share_display": "6", "freshness_pct": 38.8, "age_days": 9.6, "influence_label": "Low", "duplicate_count": 1, "topics": ["Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharmaceuticals Inc Revenue Breakdown \u2013 NASDAQ:AUPH", "summary": "Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) generated $283.06 million USD in revenue last year, primarily from its Therapeutic Drugs segment. This marks an increase from the previous year's $235.13 million USD. The United States was the largest contributor to revenue, accounting for $263.84 million USD.", "url": "https://www.tradingview.com/symbols/NASDAQ-AUPH/financials-segments", "source_link": "https://www.tradingview.com/symbols/NASDAQ-AUPH/financials-segments", "source_link_is_lookup": false, "source_name": "TradingView", "published_at": "2026-08-01T06:09:57", "published_display": "01 Aug 2026 06:09", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.016119, "evidence_share": 1.8, "evidence_share_display": "1.8", "freshness_pct": 16.8, "age_days": 12.9, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharmaceuticals Inc (AUPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Aurinia Pharmaceuticals Inc (AUPH), focusing on its price momentum, support and resistance levels, and various technical indicators. The stock currently trades between a resistance of $16.58 and support of $14.31, making it suitable for range-bound swing trading. While individual indicators show mixed signals (e.g., MACD as Sell, StochRSI as Buy), the overall technical analysis and moving averages currently suggest a Neutral signal for Aurinia Pharmaceuticals Inc.", "url": "https://www.tradingkey.com/markets/stocks/auph/technical", "source_link": "https://www.tradingkey.com/markets/stocks/auph/technical", "source_link_is_lookup": false, "source_name": "TradingKey", "published_at": "2026-07-30T09:11:51", "published_display": "30 Jul 2026 09:11", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000377, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.6, "age_days": 14.7, "influence_label": "Low", "duplicate_count": 1, "topics": ["Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharmaceuticals Inc (AUPH) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Aurinia Pharmaceuticals Inc (AUPH), detailing its current risk score, beta value, and various volatility and liquidity metrics. AUPH has a risk assessment score of 7.19, ranking 16 out of 384 in its industry, and a beta of 1.43, indicating higher volatility compared to the S&P 500. The report also highlights its historical daily returns, maximum drawdowns, and Sharpe Ratios over different periods.", "url": "https://www.tradingkey.com/markets/stocks/auph/risk-assesment", "source_link": "https://www.tradingkey.com/markets/stocks/auph/risk-assesment", "source_link_is_lookup": false, "source_name": "TradingKey", "published_at": "2026-07-30T06:51:46", "published_display": "30 Jul 2026 06:51", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.025391, "evidence_share": 2.8, "evidence_share_display": "2.8", "freshness_pct": 23.0, "age_days": 14.8, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences", "Financial Markets", "Finance"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharma earnings up next as growth momentum faces test By Investing.com", "summary": "Aurinia Pharmaceuticals Inc. is set to release its second-quarter results, with analysts expecting earnings of $0.23 per share on revenue of $80.6 million. Investors will focus on the continued revenue growth of its lupus treatment LUPKYNIS and the company's profit margins, especially since sequential EPS estimates have declined despite rising revenue forecasts. Wall Street maintains a \"buy\" rating for the stock, with a mean price target of $17.00.", "url": "https://m.au.investing.com/news/earnings/aurinia-pharma-earnings-up-next-as-growth-momentum-faces-test-93CH-4560884?ampMode=1", "source_link": "https://m.au.investing.com/news/earnings/aurinia-pharma-earnings-up-next-as-growth-momentum-faces-test-93CH-4560884?ampMode=1", "source_link_is_lookup": false, "source_name": "Investing.com Australia", "published_at": "2026-07-29T16:39:57", "published_display": "29 Jul 2026 16:39", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Operating deterioration", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.01938, "evidence_share": 2.2, "evidence_share_display": "2.2", "freshness_pct": 11.8, "age_days": 15.4, "influence_label": "Low", "duplicate_count": 3, "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharmaceuticals Inc (AUPH) Valuation: PE, PB & Fair Value Analysis", "summary": "Aurinia Pharmaceuticals Inc (AUPH) has a current valuation score of 5.10, placing it in the lower ranks of the Biotechnology & Medical Research industry. Its P/E ratio is 6.71, significantly below its recent high but above its recent low. Key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.", "url": "https://www.tradingkey.com/markets/stocks/auph/company-valuation", "source_link": "https://www.tradingkey.com/markets/stocks/auph/company-valuation", "source_link_is_lookup": false, "source_name": "TradingKey", "published_at": "2026-07-29T09:39:57", "published_display": "29 Jul 2026 09:39", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 43, "tone_signals": ["Negative financial language"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.015047, "evidence_share": 1.7, "evidence_share_display": "1.7", "freshness_pct": 11.3, "age_days": 15.7, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharmaceuticals Inc. Revenue Breakdown \u2013 LS:A1W7D4", "summary": "Aurinia Pharmaceuticals Inc. generated \u20ac241.00 million in revenue last year, primarily from its Therapeutic Drugs segment. This represents an increase from the previous year's revenue of \u20ac227.13 million. The United States was the largest contributor to this revenue, accounting for \u20ac224.64 million last year.", "url": "https://www.tradingview.com/symbols/LS-A1W7D4/financials-segments", "source_link": "https://www.tradingview.com/symbols/LS-A1W7D4/financials-segments", "source_link_is_lookup": false, "source_name": "TradingView", "published_at": "2026-07-26T23:09:26", "published_display": "26 Jul 2026 23:09", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.006331, "evidence_share": 0.7, "evidence_share_display": "0.7", "freshness_pct": 8.1, "age_days": 18.2, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "AUPH|Aurinia Pharmaceuticals Inc|Price:15.400|Chg%:+0.160", "summary": "Aurinia Pharmaceuticals Inc. (AUPH) shows healthy fundamentals and high growth potential, though its valuation is considered fair. Analysts have given the stock a \"Buy\" rating with a target price of $17.00, suggesting an 8.70% upside. The company specializes in therapies for autoimmune diseases, with its primary product LUPKYNIS for lupus nephritis, and revenue has grown significantly over the past three years.", "url": "https://www.tradingkey.com/markets/stocks/auph", "source_link": "https://www.tradingkey.com/markets/stocks/auph", "source_link_is_lookup": false, "source_name": "TradingKey", "published_at": "2026-07-24T18:43:38", "published_display": "24 Jul 2026 18:43", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.007928, "evidence_share": 0.9, "evidence_share_display": "0.9", "freshness_pct": 6.0, "age_days": 20.3, "influence_label": "Low", "duplicate_count": 3, "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "TradingKey", "summary": "This article provides an in-depth cash flow statement analysis for Aurinia Pharmaceuticals Inc (AUPH), offering both quarterly and annual data. It details operating, investing, and financing cash flows, along with related financial metrics like capital expenditures and free cash flow. The page also includes an FAQ section explaining key cash flow concepts and their relevance to AUPH's financial health.", "url": "https://www.tradingkey.com/markets/stocks/auph/cash-flow", "source_link": "https://www.tradingkey.com/markets/stocks/auph/cash-flow", "source_link_is_lookup": false, "source_name": "TradingKey", "published_at": "2026-07-24T18:43:38", "published_display": "24 Jul 2026 18:43", "source_kind": "publisher", "company_focus": 0.86, "company_focus_pct": 86, "company_focus_label": "Company discussed", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.003967, "evidence_share": 0.4, "evidence_share_display": "0.4", "freshness_pct": 6.0, "age_days": 20.3, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences", "Financial Markets"], "evidence_basis": "archived_article", "score_included": true}, {"title": "AUPH Q2'26 Earnings: revenue estimate is 80.45M USD", "summary": "Aurinia Pharmaceuticals Inc. (AUPH) is scheduled to release its Q2'26 earnings on July 30th. The company anticipates revenue of $80.45 million and earnings per share (EPS) of $0.24 for the quarter. This article provides a historical overview of AUPH's reported and estimated revenues and EPS for previous quarters.", "url": "https://www.tradingview.com/news/tradingview:62d7b140e3231:0-auph-q2-26-earnings-revenue-estimate-is-80-45m-usd", "source_link": "https://www.tradingview.com/news/tradingview:62d7b140e3231:0-auph-q2-26-earnings-revenue-estimate-is-80-45m-usd", "source_link_is_lookup": false, "source_name": "TradingView", "published_at": "2026-07-23T11:10:40", "published_display": "23 Jul 2026 11:10", "source_kind": "publisher", "company_focus": 0.86, "company_focus_pct": 86, "company_focus_label": "Company discussed", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.004041, "evidence_share": 0.4, "evidence_share_display": "0.4", "freshness_pct": 5.0, "age_days": 21.7, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Liquidity Mapping Around (AUPH) Price Events", "summary": "Aurinia Pharmaceuticals Inc (AUPH) is showing weak near and mid-term sentiment, despite a strong long-term outlook. The stock is currently testing support, and if it holds, resistance is expected next, with an exceptional risk-reward setup targeting an 11.4% gain. The article outlines different AI-generated trading strategies for various risk profiles, including position, momentum breakout, and risk hedging strategies.", "url": "https://news.stocktradersdaily.com/news_release/17/Liquidity_Mapping_Around_AUPH_Price_Events_072326094802_1784814482.html", "source_link": "https://news.stocktradersdaily.com/news_release/17/Liquidity_Mapping_Around_AUPH_Price_Events_072326094802_1784814482.html", "source_link_is_lookup": false, "source_name": "Stock Traders Daily", "published_at": "2026-07-23T10:10:40", "published_display": "23 Jul 2026 10:10", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.018559, "evidence_share": 2.1, "evidence_share_display": "2.1", "freshness_pct": 11.7, "age_days": 21.7, "influence_label": "Low", "duplicate_count": 1, "topics": ["Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharmaceuticals Inc (AUPH) Earnings, Actual EPS, EPS Estimates & Results", "summary": "This article provides an overview of Aurinia Pharmaceuticals Inc.'s (AUPH) earnings data, including upcoming and historical EPS and revenue reports. It highlights past earning beats and lists recent news and trending discussions related to the company. The company's next earnings report for Q2 '26 is estimated for July 30, with an estimated EPS of $0.24 and revenue of $80.45 million.", "url": "https://stocktwits.com/symbol/AUPH/earnings", "source_link": "https://stocktwits.com/symbol/AUPH/earnings", "source_link_is_lookup": false, "source_name": "Stocktwits", "published_at": "2026-07-23T01:10:40", "published_display": "23 Jul 2026 01:10", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.006236, "evidence_share": 0.7, "evidence_share_display": "0.7", "freshness_pct": 4.7, "age_days": 22.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharmaceuticals Inc (AUPH) Fundamental & Financial Data", "summary": "This article provides fundamental and financial data for Aurinia Pharmaceuticals Inc (AUPH), including its current stock price, market capitalization, P/E ratio, and 52-week high/low. It also lists recent news regarding the company, such as its upgrade to \"Strong Buy\" by Zacks and the initiation of a new study for its drug LUPKYNIS in lupus nephritis patients. The page also shows trending tickers and community discussions related to other stocks.", "url": "https://stocktwits.com/symbol/AUPH/fundamentals", "source_link": "https://stocktwits.com/symbol/AUPH/fundamentals", "source_link_is_lookup": false, "source_name": "Stocktwits", "published_at": "2026-07-22T17:40:30", "published_display": "22 Jul 2026 17:40", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "positive", "sentiment_pct": 69, "tone_signals": ["Analyst upgrade"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.007943, "evidence_share": 0.9, "evidence_share_display": "0.9", "freshness_pct": 4.5, "age_days": 22.4, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences", "Financial Markets"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharmaceuticals (AUPH) Q1 2026 earnings summary", "summary": "Aurinia Pharmaceuticals reported strong Q1 2026 results, with total revenue increasing 24% year-over-year to $77.7 million, driven by higher LUPKYNIS sales. Net income surged 48% to $34.4 million, and operating cash flows significantly improved. The company also saw significant management changes and provided positive full-year 2026 guidance.", "url": "https://quartr.com/events/aurinia-pharmaceuticals-inc-auph-q1-2026_3sQHoEI2", "source_link": "https://quartr.com/events/aurinia-pharmaceuticals-inc-auph-q1-2026_3sQHoEI2", "source_link_is_lookup": false, "source_name": "Quartr", "published_at": "2026-07-19T15:41:20", "published_display": "19 Jul 2026 15:41", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "positive", "sentiment_pct": 76, "tone_signals": ["Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.007724, "evidence_share": 0.9, "evidence_share_display": "0.9", "freshness_pct": 2.9, "age_days": 25.5, "influence_label": "Low", "duplicate_count": 4, "topics": ["Earnings", "Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharmaceuticals (AUPH) Proxy Filing Summary", "summary": "Aurinia Pharmaceuticals (AUPH) released a proxy filing summary detailing strong 2024 LUPKYNIS sales, cash flow, and share repurchases. Shareholders will vote on directors, auditor appointment, a non-binding say-on-pay, and an amendment to the Equity Incentive Plan. The company also highlighted its updated corporate governance, including a reduced board size and independent committees.", "url": "https://quartr.com/events/aurinia-pharmaceuticals-auph-proxy-filing_3sQHXno5", "source_link": "https://quartr.com/events/aurinia-pharmaceuticals-auph-proxy-filing_3sQHXno5", "source_link_is_lookup": false, "source_name": "Quartr", "published_at": "2026-07-19T14:41:00", "published_display": "19 Jul 2026 14:41", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "positive", "sentiment_pct": 66, "tone_signals": ["Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.005719, "evidence_share": 0.6, "evidence_share_display": "0.6", "freshness_pct": 2.9, "age_days": 25.5, "influence_label": "Low", "duplicate_count": 3, "topics": ["Earnings", "Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharmaceuticals (AUPH) Jefferies 2024 Global Healthcare Conference Summary", "summary": "Aurinia Pharmaceuticals presented a summary of its performance and outlook at the Jefferies 2024 Global Healthcare Conference. The company reported strong LUPKYNIS revenue growth, projecting to be cash flow positive in Q2, and highlighted efforts in market development, patient engagement, and product differentiation. Aurinia Pharmaceuticals detailed the drug's clinical benefits, market expansion plans, and financial health, emphasizing its significant cash reserves and non-dilutive capital from the Otsuka partnership.", "url": "https://quartr.com/events/aurinia-pharmaceuticals-inc-auph-jefferies-2024-global-healthcare-conference_3sQHujQp", "source_link": "https://quartr.com/events/aurinia-pharmaceuticals-inc-auph-jefferies-2024-global-healthcare-conference_3sQHujQp", "source_link_is_lookup": false, "source_name": "Quartr", "published_at": "2026-07-18T06:10:47", "published_display": "18 Jul 2026 06:10", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 55, "tone_signals": ["Operating growth", "Dilution risk"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.003962, "evidence_share": 0.4, "evidence_share_display": "0.4", "freshness_pct": 2.4, "age_days": 26.9, "influence_label": "Low", "duplicate_count": 2, "topics": ["Earnings", "Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Crinetics Pharmaceuticals (CRNX) Stock Looks Fully Valued While Returns Stay Very Strong", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Crinetics+Pharmaceuticals+%28CRNX%29+Stock+Looks+Fully+Valued+While+Returns+Stay+Very+Strong%22+%22simplywall.st%22", "source_link_is_lookup": true, "source_name": "simplywall.st", "published_at": "2026-07-17T17:44:25.256245+00:00", "published_display": "17 Jul 2026 17:44", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "positive", "sentiment_pct": 60, "tone_signals": ["Positive financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 6e-06, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.0, "age_days": 27.4, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}], "by_tier": {"direct": [{"title": "Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Consensus Recommendation of \"Hold\" from Brokerages", "summary": "Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has received a consensus \"Hold\" rating from six brokerages, with an average 12-month price target of $17.67. This comes despite its CEO and other insiders acquiring a significant number of shares recently. The company beat EPS estimates but missed revenue forecasts in its latest quarterly report.", "url": "https://www.marketbeat.com/instant-alerts/aurinia-pharmaceuticals-inc-nasdaqauph-receives-consensus-recommendation-of-hold-from-brokerages-2026-08-09", "source_link": "https://www.marketbeat.com/instant-alerts/aurinia-pharmaceuticals-inc-nasdaqauph-receives-consensus-recommendation-of-hold-from-brokerages-2026-08-09", "source_link_is_lookup": false, "source_name": "MarketBeat", "published_at": "2026-08-09T19:40:36", "published_display": "09 Aug 2026 19:40", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["AUPH"], "target_provider_symbol": "AUPH", "cross_listing": false, "source_names": ["MarketBeat"], "source_kind": "publisher", "story_key": "b001c413a094be240dfdbae4b457aa3d42a7f916ae26a300e487b1d2a11e5368", "target_scope": "Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Consensus Recommendation of \"Hold\" from Brokerages Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has received a consensus \"Hold\" rating from six brokerages, with an average 12-month price target of $17.67.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.567, "provider_directional_mass": 0.1029, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.29, "sentiment": "positive", "sentiment_pct": 66, "tone_signals": ["Beat expectations"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.059143, "evidence_share": 6.6, "evidence_share_display": "6.6", "freshness_pct": 37.0, "age_days": 4.3, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences", "Earnings", "Financial Markets"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharmaceuticals (NASDAQ:AUPH) Downgraded by Wall Street Zen to Buy", "summary": "Wall Street Zen downgraded Aurinia Pharmaceuticals (NASDAQ:AUPH) from \"strong buy\" to \"buy\" due to revenue falling short of expectations, despite beating EPS estimates. The broader analyst consensus remains \"hold\" with an average price target of $17.67. Insider buying, including a significant purchase by the CEO, indicates confidence in the company, with insiders owning 10.4% of the stock.", "url": "https://www.marketbeat.com/instant-alerts/aurinia-pharmaceuticals-nasdaqauph-downgraded-by-wall-street-zen-to-buy-2026-08-08", "source_link": "https://www.marketbeat.com/instant-alerts/aurinia-pharmaceuticals-nasdaqauph-downgraded-by-wall-street-zen-to-buy-2026-08-08", "source_link_is_lookup": false, "source_name": "MarketBeat", "published_at": "2026-08-08T05:40:00", "published_display": "08 Aug 2026 05:40", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["AUPH", "AUPH.ARCHIVE"], "target_provider_symbol": "AUPH", "cross_listing": false, "source_names": ["MarketBeat"], "source_kind": "publisher", "story_key": "9ca75cf7fab6e061c0598bc08e393e74cf2c3a9caeba01201bee79454cbdbd06", "target_scope": "Aurinia Pharmaceuticals (NASDAQ:AUPH) Downgraded by Wall Street Zen to Buy Wall Street Zen downgraded Aurinia Pharmaceuticals (NASDAQ:AUPH) from \"strong buy\" to \"buy\" due to revenue falling short of expectations, despite beating EPS estimates.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.559, "provider_directional_mass": 0.0048, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 66, "tone_signals": ["Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.086856, "evidence_share": 9.6, "evidence_share_display": "9.6", "freshness_pct": 44.2, "age_days": 5.9, "influence_label": "Medium", "duplicate_count": 1, "topics": ["Earnings", "Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharmaceuticals Inc. 2026: Revenue $83.22M, EPS $0.28\u2014 10-Q Summary", "summary": "Aurinia Pharmaceuticals Inc. reported its 2026 quarterly results, with revenue reaching $83.22M and diluted EPS of $0.28, marking significant increases compared to the previous year. The growth was attributed to higher product sales, improved operating performance, and increased market penetration of LUPKYNIS. The company also highlighted clinical advancements, pipeline expansion, and enhanced manufacturing capacity.", "url": "https://www.tradingview.com/news/tradingview:b02ebfe2663ee:0-aurinia-pharmaceuticals-inc-2026-revenue-83-22m-eps-0-28-10-q-summary", "source_link": "https://www.tradingview.com/news/tradingview:b02ebfe2663ee:0-aurinia-pharmaceuticals-inc-2026-revenue-83-22m-eps-0-28-10-q-summary", "source_link_is_lookup": false, "source_name": "TradingView", "published_at": "2026-08-06T23:41:36", "published_display": "06 Aug 2026 23:41", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["AUPH"], "target_provider_symbol": "AUPH", "cross_listing": false, "source_names": ["TradingView"], "source_kind": "publisher", "story_key": "276a2694bebca6e88369dcb55473a9a9872f1f8d556dddace8c03d984e484bf7", "target_scope": "Aurinia Pharmaceuticals Inc. Aurinia Pharmaceuticals Inc.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.701, "provider_directional_mass": 0.6433, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 80, "tone_signals": ["Improving financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.119418, "evidence_share": 13.3, "evidence_share_display": "13.3", "freshness_pct": 37.2, "age_days": 7.1, "influence_label": "Medium", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharmaceuticals (AUPH) Earnings Date and Reports 2026", "summary": "Aurinia Pharmaceuticals (AUPH) announced its Q2 2026 earnings, reporting an EPS of $0.28, surpassing the consensus estimate of $0.24. However, quarterly revenue of $58.57 million fell short of analysts' expectations. The company also provided FY 2026 revenue guidance of $315.0 million-$325.0 million, slightly below the consensus estimate.", "url": "https://www.marketbeat.com/stocks/NASDAQ/AUPH/earnings", "source_link": "https://www.marketbeat.com/stocks/NASDAQ/AUPH/earnings", "source_link_is_lookup": false, "source_name": "MarketBeat", "published_at": "2026-08-06T23:41:36", "published_display": "06 Aug 2026 23:41", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["AUPH"], "target_provider_symbol": "AUPH", "cross_listing": false, "source_names": ["MarketBeat"], "source_kind": "publisher", "story_key": "a40a2ed4af99ef843e95f974ae2ecc34e40f9aa8a377982a067dffe7aff2c83f", "target_scope": "Aurinia Pharmaceuticals (AUPH) Earnings Date and Reports 2026 Aurinia Pharmaceuticals (AUPH) announced its Q2 2026 earnings, reporting an EPS of $0.28, surpassing the consensus estimate of $0.24.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.721, "provider_directional_mass": 0.2512, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 16, "tone_signals": ["Missed expectations", "Operating deterioration"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.129519, "evidence_share": 14.4, "evidence_share_display": "14.4", "freshness_pct": 37.2, "age_days": 7.1, "influence_label": "Medium", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences", "Financial Markets"], "evidence_basis": "archived_article", "score_included": true}, {"title": "How Investors Are Reacting To Aurinia Pharmaceuticals (AUPH) Strong Q2 Earnings And Reaffirmed 2026 Guidance", "summary": "Aurinia Pharmaceuticals reported strong Q2 2026 results with increased revenue and net income, alongside reaffirming its 2026 revenue guidance. This performance reinforces the company's near-term outlook for its LUPKYNIS drug, despite ongoing concerns about its reliance on a single product and future pipeline development. The article discusses how these results impact the investment narrative, highlighting both the company's current profitability and potential long-term risks.", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/how-investors-are-reacting-to-aurinia-pharmaceuticals-auph-s/amp", "source_link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/how-investors-are-reacting-to-aurinia-pharmaceuticals-auph-s/amp", "source_link_is_lookup": false, "source_name": "Simply Wall St", "published_at": "2026-08-06T21:11:18", "published_display": "06 Aug 2026 21:11", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["AUPH", "BIIB", "GILD", "MRNA", "PFE"], "target_provider_symbol": "AUPH", "cross_listing": false, "source_names": ["Simply Wall St"], "source_kind": "publisher", "story_key": "efce470231476f4445ca257182493e0979d7c430229d0829e42fd6d2a13032bd", "target_scope": "How Investors Are Reacting To Aurinia Pharmaceuticals (AUPH) Strong Q2 Earnings And Reaffirmed 2026 Guidance Aurinia Pharmaceuticals reported strong Q2 2026 results with increased revenue and net income, alongside reaffirming its 2026 revenue guidance.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.681, "provider_directional_mass": 0.4223, "relevance_score": 0.97206, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.872, "sentiment": "neutral", "sentiment_pct": 52, "tone_signals": ["Going Concern", "Improving financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.048425, "evidence_share": 5.4, "evidence_share_display": "5.4", "freshness_pct": 36.6, "age_days": 7.2, "influence_label": "Low", "duplicate_count": 2, "topics": ["Earnings", "Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress", "summary": "Aurinia Pharmaceuticals announced strong financial results for the three and six months ended June 30, 2026, with significant increases in total revenue, net product sales, and net income compared to the previous year. The company also reiterated its 2026 revenue guidance and provided updates on its clinical development programs, including the initiation of the PRESERVE study for LUPKYNIS and further clinical development of aritinercept for autoimmune diseases.", "url": "https://www.biospace.com/press-releases/aurinia-pharmaceuticals-reports-financial-results-for-the-three-and-six-months-ended-june-30-2026-and-provides-update-on-recent-business-progress", "source_link": "https://www.biospace.com/press-releases/aurinia-pharmaceuticals-reports-financial-results-for-the-three-and-six-months-ended-june-30-2026-and-provides-update-on-recent-business-progress", "source_link_is_lookup": false, "source_name": "BioSpace", "published_at": "2026-08-06T18:11:18", "published_display": "06 Aug 2026 18:11", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["AUPH"], "target_provider_symbol": "AUPH", "cross_listing": false, "source_names": ["BioSpace"], "source_kind": "publisher", "story_key": "4826ef781757b17f4a9a8f2e12168321e1869124779a484cc20a292b40e3dc64", "target_scope": "Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress Aurinia Pharmaceuticals announced strong financial results for the three and six months ended June 30, 2026, with significant increases in total revenue, net product sales, and net income compared to the previous year.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.461, "provider_directional_mass": 0.425, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.047914, "evidence_share": 5.3, "evidence_share_display": "5.3", "freshness_pct": 36.0, "age_days": 7.4, "influence_label": "Low", "duplicate_count": 2, "topics": ["Earnings", "Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Earnings Flash (AUPH) Aurinia Pharmaceuticals Inc. Reports Q2 Revenue $83.2M, Vs. FactSet Est of $80.4M", "summary": "Aurinia Pharmaceuticals Inc. (AUPH) reported Q2 revenue of $83.2 million, surpassing the FactSet estimate of $80.4 million. The article also briefly mentions Unity Software's Q4 earnings, which showed a 35% year-over-year revenue increase to $609 million, exceeding the consensus estimate, despite a quarterly loss of 66 cents per share.", "url": "https://www.moomoo.com/news/post/74242756/earnings-flash-auph-aurinia-pharmaceuticals-inc-reports-q2-revenue-83", "source_link": "https://www.moomoo.com/news/post/74242756/earnings-flash-auph-aurinia-pharmaceuticals-inc-reports-q2-revenue-83", "source_link_is_lookup": false, "source_name": "Moomoo", "published_at": "2026-08-06T16:40:03", "published_display": "06 Aug 2026 16:40", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["AUPH"], "target_provider_symbol": "AUPH", "cross_listing": false, "source_names": ["Moomoo"], "source_kind": "publisher", "story_key": "5a03b2d7889886360ab75f4a266f2570899dabed441c6524db7f9d5ee5adcec5", "target_scope": "Earnings Flash (AUPH) Aurinia Pharmaceuticals Inc. Aurinia Pharmaceuticals Inc. (AUPH) reported Q2 revenue of $83.2 million, surpassing the FactSet estimate of $80.4 million.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.489, "provider_directional_mass": 0.3335, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.524, "sentiment": "neutral", "sentiment_pct": 55, "tone_signals": ["Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.048219, "evidence_share": 5.4, "evidence_share_display": "5.4", "freshness_pct": 35.7, "age_days": 7.4, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharmaceuticals posts Q2 revenue $83.2M, net income $37.4M; reiterates 2026 guidance", "summary": "Aurinia Pharmaceuticals announced its Q2 2026 financial results, reporting $83.2 million in revenue and $37.4 million in net income. The company also reiterated its full-year 2026 revenue guidance of $315 million to $325 million. Key highlights include strong sales for LUPKYNIS and advancements in clinical development programs.", "url": "https://www.tradingview.com/news/tradingview:69458a1583f25:0-aurinia-pharmaceuticals-posts-q2-revenue-83-2m-net-income-37-4m-reiterates-2026-guidance", "source_link": "https://www.tradingview.com/news/tradingview:69458a1583f25:0-aurinia-pharmaceuticals-posts-q2-revenue-83-2m-net-income-37-4m-reiterates-2026-guidance", "source_link_is_lookup": false, "source_name": "TradingView", "published_at": "2026-08-06T13:10:38", "published_display": "06 Aug 2026 13:10", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["AUPH"], "target_provider_symbol": "AUPH", "cross_listing": false, "source_names": ["TradingView"], "source_kind": "publisher", "story_key": "ac996a16e8c9cee33930377c6f2152f91e603d155c6b38301cdbd337ee7560ee", "target_scope": "Aurinia Pharmaceuticals posts Q2 revenue $83.2M, net income $37.4M Aurinia Pharmaceuticals announced its Q2 2026 financial results, reporting $83.2 million in revenue and $37.4 million in net income.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.559, "provider_directional_mass": 0.4667, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 66, "tone_signals": ["Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.068743, "evidence_share": 7.6, "evidence_share_display": "7.6", "freshness_pct": 35.0, "age_days": 7.6, "influence_label": "Medium", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "AUPH: Strong revenue and net income growth driven by LUPKYNIS, with robust 2026 outlook", "summary": "Aurinia Pharmaceuticals (AUPH) reported strong double-digit year-over-year growth in revenue and net income, primarily due to LUPKYNIS sales and improved margins. The company's 2026 guidance anticipates continued growth in revenue and product sales. Additionally, new clinical programs and share repurchases indicate ongoing positive business momentum for AUPH.", "url": "https://www.tradingview.com/news/urn:summary_document_report:quartr.com:3976831:0", "source_link": "https://www.tradingview.com/news/urn:summary_document_report:quartr.com:3976831:0", "source_link_is_lookup": false, "source_name": "TradingView", "published_at": "2026-08-06T12:11:18", "published_display": "06 Aug 2026 12:11", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["AUPH"], "target_provider_symbol": "AUPH", "cross_listing": false, "source_names": ["TradingView"], "source_kind": "publisher", "story_key": "b589d2f94b7d095047d28d04e8a8210fa621b434907ba4320b7fd597bb88e9fc", "target_scope": "Aurinia Pharmaceuticals (AUPH) reported strong double-digit year-over-year growth in revenue and net income, primarily due to LUPKYNIS sales and improved margins.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.653, "provider_directional_mass": 0.8365, "relevance_score": 1.0, "company_focus": 0.86, "company_focus_pct": 86, "company_focus_label": "Company discussed", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 80, "tone_signals": ["Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.087201, "evidence_share": 9.7, "evidence_share_display": "9.7", "freshness_pct": 34.8, "age_days": 7.6, "influence_label": "Medium", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Targets Myasthenia Gravis With New Aritinercept Trial, Expanding Its Growth Story", "summary": "Aurinia Pharmaceuticals (AUPH) is expanding its clinical pipeline with a new Phase 1/2 trial for aritinercept, targeting generalized myasthenia gravis. The double-blind, placebo-controlled study will investigate the safety and efficacy of the dual BAFF/APRIL inhibitor in improving muscle weakness in this chronic autoimmune condition. This move diversifies Aurinia's portfolio beyond kidney disease into neurology, potentially supporting a higher valuation if early data are promising.", "url": "https://www.theglobeandmail.com/investing/markets/stocks/AUPH-Q/pressreleases/3641494/aurinia-targets-myasthenia-gravis-with-new-aritinercept-trial-expanding-its-growth-story", "source_link": "https://www.theglobeandmail.com/investing/markets/stocks/AUPH-Q/pressreleases/3641494/aurinia-targets-myasthenia-gravis-with-new-aritinercept-trial-expanding-its-growth-story", "source_link_is_lookup": false, "source_name": "The Globe and Mail", "published_at": "2026-08-05T00:04:51", "published_display": "05 Aug 2026 00:04", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["AUPH"], "target_provider_symbol": "AUPH", "cross_listing": false, "source_names": ["The Globe and Mail"], "source_kind": "publisher", "story_key": "b1c00220614ec5098ab52a593126afcbb044399416865ac60c806b9549aff67e", "target_scope": "Aurinia Targets Myasthenia Gravis With New Aritinercept Trial, Expanding Its Growth Story Aurinia Pharmaceuticals (AUPH) is expanding its clinical pipeline with a new Phase 1/2 trial for aritinercept, targeting generalized myasthenia gravis. This move diversifies Aurinia's portfolio beyond kidney disease into neurology, potentially supporting a higher valuation if early data are promising.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": 0.3265, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.002641, "evidence_share": 0.3, "evidence_share_display": "0.3", "freshness_pct": 4.2, "age_days": 9.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "(AUPH) Movement as an Input in Quant Signal Sets", "summary": "Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is showing weak near and mid-term sentiment, challenging a positive long-term outlook, with support currently being tested. The article provides AI-generated trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. It highlights a significant 42.0:1 risk-reward setup targeting an 11.4% gain versus a 0.3% risk.", "url": "https://news.stocktradersdaily.com/news_release/14/AUPH_Movement_as_an_Input_in_Quant_Signal_Sets_080426013602_1785864962.html", "source_link": "https://news.stocktradersdaily.com/news_release/14/AUPH_Movement_as_an_Input_in_Quant_Signal_Sets_080426013602_1785864962.html", "source_link_is_lookup": false, "source_name": "Stock Traders Daily", "published_at": "2026-08-04T13:36:00", "published_display": "04 Aug 2026 13:36", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["AUPH"], "target_provider_symbol": "AUPH", "cross_listing": false, "source_names": ["Stock Traders Daily"], "source_kind": "publisher", "story_key": "23eaa41d8085b4e814d7a7ffcaee1a49b59652b4e5db3a8e0d5959003ec70066", "target_scope": "(AUPH) Movement as an Input in Quant Signal Sets Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is showing weak near and mid-term sentiment, challenging a positive long-term outlook, with support currently being tested.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.424, "provider_directional_mass": 0.0578, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.5, "sentiment": "neutral", "sentiment_pct": 55, "tone_signals": ["Positive financial language"], "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.053872, "evidence_share": 6.0, "evidence_share_display": "6", "freshness_pct": 38.8, "age_days": 9.6, "influence_label": "Low", "duplicate_count": 1, "topics": ["Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharmaceuticals Inc Revenue Breakdown \u2013 NASDAQ:AUPH", "summary": "Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) generated $283.06 million USD in revenue last year, primarily from its Therapeutic Drugs segment. This marks an increase from the previous year's $235.13 million USD. The United States was the largest contributor to revenue, accounting for $263.84 million USD.", "url": "https://www.tradingview.com/symbols/NASDAQ-AUPH/financials-segments", "source_link": "https://www.tradingview.com/symbols/NASDAQ-AUPH/financials-segments", "source_link_is_lookup": false, "source_name": "TradingView", "published_at": "2026-08-01T06:09:57", "published_display": "01 Aug 2026 06:09", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["AUPH", "AUPH.ARCHIVE"], "target_provider_symbol": "AUPH", "cross_listing": false, "source_names": ["TradingView"], "source_kind": "publisher", "story_key": "e9d1d747197e1f16c0aabdc77f69cf5c575676bf26e19ca61a201a3a78e055d0", "target_scope": "Aurinia Pharmaceuticals Inc Revenue Breakdown \u2013 NASDAQ:AUPH Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) generated $283.06 million USD in revenue last year, primarily from its Therapeutic Drugs segment.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": 0.1223, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.016119, "evidence_share": 1.8, "evidence_share_display": "1.8", "freshness_pct": 16.8, "age_days": 12.9, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharmaceuticals Inc (AUPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Aurinia Pharmaceuticals Inc (AUPH), focusing on its price momentum, support and resistance levels, and various technical indicators. The stock currently trades between a resistance of $16.58 and support of $14.31, making it suitable for range-bound swing trading. While individual indicators show mixed signals (e.g., MACD as Sell, StochRSI as Buy), the overall technical analysis and moving averages currently suggest a Neutral signal for Aurinia Pharmaceuticals Inc.", "url": "https://www.tradingkey.com/markets/stocks/auph/technical", "source_link": "https://www.tradingkey.com/markets/stocks/auph/technical", "source_link_is_lookup": false, "source_name": "TradingKey", "published_at": "2026-07-30T09:11:51", "published_display": "30 Jul 2026 09:11", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["AUPH"], "target_provider_symbol": "AUPH", "cross_listing": false, "source_names": ["TradingKey"], "source_kind": "publisher", "story_key": "ea459d0ee4d9e16a274463cc33c2deba7fade03680aaa6b6b1ce1787fd8e1382", "target_scope": "Aurinia Pharmaceuticals Inc (AUPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages This article provides a technical analysis of Aurinia Pharmaceuticals Inc (AUPH), focusing on its price momentum, support and resistance levels, and various technical indicators. While individual indicators show mixed signals (e.g., MACD as Sell, StochRSI as Buy), the overall technical analysis and moving averages currently suggest a Neutral signal for Aurinia Pharmaceuticals Inc.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": 0.2208, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000377, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.6, "age_days": 14.7, "influence_label": "Low", "duplicate_count": 1, "topics": ["Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharmaceuticals Inc (AUPH) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Aurinia Pharmaceuticals Inc (AUPH), detailing its current risk score, beta value, and various volatility and liquidity metrics. AUPH has a risk assessment score of 7.19, ranking 16 out of 384 in its industry, and a beta of 1.43, indicating higher volatility compared to the S&P 500. The report also highlights its historical daily returns, maximum drawdowns, and Sharpe Ratios over different periods.", "url": "https://www.tradingkey.com/markets/stocks/auph/risk-assesment", "source_link": "https://www.tradingkey.com/markets/stocks/auph/risk-assesment", "source_link_is_lookup": false, "source_name": "TradingKey", "published_at": "2026-07-30T06:51:46", "published_display": "30 Jul 2026 06:51", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["AUPH"], "target_provider_symbol": "AUPH", "cross_listing": false, "source_names": ["TradingKey"], "source_kind": "publisher", "story_key": "53581bde6230d0dde31665689fc93d389460ccddf2c5386f0b2330b8e561e675", "target_scope": "Aurinia Pharmaceuticals Inc (AUPH) Risk Assessment: Volatility, Financial Risk & Investment Risk This article provides a risk assessment for Aurinia Pharmaceuticals Inc (AUPH), detailing its current risk score, beta value, and various volatility and liquidity metrics.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": 0.0426, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.025391, "evidence_share": 2.8, "evidence_share_display": "2.8", "freshness_pct": 23.0, "age_days": 14.8, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences", "Financial Markets", "Finance"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharma earnings up next as growth momentum faces test By Investing.com", "summary": "Aurinia Pharmaceuticals Inc. is set to release its second-quarter results, with analysts expecting earnings of $0.23 per share on revenue of $80.6 million. Investors will focus on the continued revenue growth of its lupus treatment LUPKYNIS and the company's profit margins, especially since sequential EPS estimates have declined despite rising revenue forecasts. Wall Street maintains a \"buy\" rating for the stock, with a mean price target of $17.00.", "url": "https://m.au.investing.com/news/earnings/aurinia-pharma-earnings-up-next-as-growth-momentum-faces-test-93CH-4560884?ampMode=1", "source_link": "https://m.au.investing.com/news/earnings/aurinia-pharma-earnings-up-next-as-growth-momentum-faces-test-93CH-4560884?ampMode=1", "source_link_is_lookup": false, "source_name": "Investing.com Australia", "published_at": "2026-07-29T16:39:57", "published_display": "29 Jul 2026 16:39", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["AUPH"], "target_provider_symbol": "AUPH", "cross_listing": false, "source_names": ["Investing.com Australia"], "source_kind": "publisher", "story_key": "a5f769b398c34b733d66ca4af264c095c36ef49e66bd8a92b70917b188a88482", "target_scope": "Aurinia Pharma earnings up next as growth momentum faces test By Investing.com Aurinia Pharmaceuticals Inc.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.502, "provider_directional_mass": 0.1379, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.939, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Operating deterioration", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.01938, "evidence_share": 2.2, "evidence_share_display": "2.2", "freshness_pct": 11.8, "age_days": 15.4, "influence_label": "Low", "duplicate_count": 3, "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharmaceuticals Inc (AUPH) Valuation: PE, PB & Fair Value Analysis", "summary": "Aurinia Pharmaceuticals Inc (AUPH) has a current valuation score of 5.10, placing it in the lower ranks of the Biotechnology & Medical Research industry. Its P/E ratio is 6.71, significantly below its recent high but above its recent low. Key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.", "url": "https://www.tradingkey.com/markets/stocks/auph/company-valuation", "source_link": "https://www.tradingkey.com/markets/stocks/auph/company-valuation", "source_link_is_lookup": false, "source_name": "TradingKey", "published_at": "2026-07-29T09:39:57", "published_display": "29 Jul 2026 09:39", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["AUPH"], "target_provider_symbol": "AUPH", "cross_listing": false, "source_names": ["TradingKey"], "source_kind": "publisher", "story_key": "51a7c30582ce5db117552eb3a789b2c663edd8818c703791c2ee644b1322b07d", "target_scope": "Aurinia Pharmaceuticals Inc (AUPH) Valuation: PE, PB & Fair Value Analysis Aurinia Pharmaceuticals Inc (AUPH) has a current valuation score of 5.10, placing it in the lower ranks of the Biotechnology & Medical Research industry.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.461, "provider_directional_mass": 0.011, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 43, "tone_signals": ["Negative financial language"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.015047, "evidence_share": 1.7, "evidence_share_display": "1.7", "freshness_pct": 11.3, "age_days": 15.7, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharmaceuticals Inc. Revenue Breakdown \u2013 LS:A1W7D4", "summary": "Aurinia Pharmaceuticals Inc. generated \u20ac241.00 million in revenue last year, primarily from its Therapeutic Drugs segment. This represents an increase from the previous year's revenue of \u20ac227.13 million. The United States was the largest contributor to this revenue, accounting for \u20ac224.64 million last year.", "url": "https://www.tradingview.com/symbols/LS-A1W7D4/financials-segments", "source_link": "https://www.tradingview.com/symbols/LS-A1W7D4/financials-segments", "source_link_is_lookup": false, "source_name": "TradingView", "published_at": "2026-07-26T23:09:26", "published_display": "26 Jul 2026 23:09", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["AUPH"], "target_provider_symbol": "AUPH", "cross_listing": false, "source_names": ["TradingView"], "source_kind": "publisher", "story_key": "dcfa1312f775f1b2068863c330b5781f291bcbc2950a1ca57bc5cb12ea8bd1de", "target_scope": "Aurinia Pharmaceuticals Inc. Aurinia Pharmaceuticals Inc.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": 0.0435, "relevance_score": 0.72, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.006331, "evidence_share": 0.7, "evidence_share_display": "0.7", "freshness_pct": 8.1, "age_days": 18.2, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "AUPH|Aurinia Pharmaceuticals Inc|Price:15.400|Chg%:+0.160", "summary": "Aurinia Pharmaceuticals Inc. (AUPH) shows healthy fundamentals and high growth potential, though its valuation is considered fair. Analysts have given the stock a \"Buy\" rating with a target price of $17.00, suggesting an 8.70% upside. The company specializes in therapies for autoimmune diseases, with its primary product LUPKYNIS for lupus nephritis, and revenue has grown significantly over the past three years.", "url": "https://www.tradingkey.com/markets/stocks/auph", "source_link": "https://www.tradingkey.com/markets/stocks/auph", "source_link_is_lookup": false, "source_name": "TradingKey", "published_at": "2026-07-24T18:43:38", "published_display": "24 Jul 2026 18:43", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["AUPH", "AUPH.ARCHIVE"], "target_provider_symbol": "AUPH", "cross_listing": false, "source_names": ["TradingKey"], "source_kind": "publisher", "story_key": "582b369f0b456a26342721db228645668dcdc4bbbf9f359ab0d42c74c24a4d57", "target_scope": "AUPH|Aurinia Pharmaceuticals Inc|Price:15.400|Chg%:+0.160 Aurinia Pharmaceuticals Inc. (AUPH) shows healthy fundamentals and high growth potential, though its valuation is considered fair.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.461, "provider_directional_mass": 0.2013, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.007928, "evidence_share": 0.9, "evidence_share_display": "0.9", "freshness_pct": 6.0, "age_days": 20.3, "influence_label": "Low", "duplicate_count": 3, "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "TradingKey", "summary": "This article provides an in-depth cash flow statement analysis for Aurinia Pharmaceuticals Inc (AUPH), offering both quarterly and annual data. It details operating, investing, and financing cash flows, along with related financial metrics like capital expenditures and free cash flow. The page also includes an FAQ section explaining key cash flow concepts and their relevance to AUPH's financial health.", "url": "https://www.tradingkey.com/markets/stocks/auph/cash-flow", "source_link": "https://www.tradingkey.com/markets/stocks/auph/cash-flow", "source_link_is_lookup": false, "source_name": "TradingKey", "published_at": "2026-07-24T18:43:38", "published_display": "24 Jul 2026 18:43", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["AUPH"], "target_provider_symbol": "AUPH", "cross_listing": false, "source_names": ["TradingKey"], "source_kind": "publisher", "story_key": "10d245014f15ac5f40d53e4d087e5068ade05c9c99f0d24428a853b478a984af", "target_scope": "This article provides an in-depth cash flow statement analysis for Aurinia Pharmaceuticals Inc (AUPH), offering both quarterly and annual data.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": 0.0134, "relevance_score": 0.72, "company_focus": 0.86, "company_focus_pct": 86, "company_focus_label": "Company discussed", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.003967, "evidence_share": 0.4, "evidence_share_display": "0.4", "freshness_pct": 6.0, "age_days": 20.3, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences", "Financial Markets"], "evidence_basis": "archived_article", "score_included": true}, {"title": "AUPH Q2'26 Earnings: revenue estimate is 80.45M USD", "summary": "Aurinia Pharmaceuticals Inc. (AUPH) is scheduled to release its Q2'26 earnings on July 30th. The company anticipates revenue of $80.45 million and earnings per share (EPS) of $0.24 for the quarter. This article provides a historical overview of AUPH's reported and estimated revenues and EPS for previous quarters.", "url": "https://www.tradingview.com/news/tradingview:62d7b140e3231:0-auph-q2-26-earnings-revenue-estimate-is-80-45m-usd", "source_link": "https://www.tradingview.com/news/tradingview:62d7b140e3231:0-auph-q2-26-earnings-revenue-estimate-is-80-45m-usd", "source_link_is_lookup": false, "source_name": "TradingView", "published_at": "2026-07-23T11:10:40", "published_display": "23 Jul 2026 11:10", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["AUPH"], "target_provider_symbol": "AUPH", "cross_listing": false, "source_names": ["TradingView"], "source_kind": "publisher", "story_key": "1cbb4127841c97388e306497e9b6a691efd008e692231cdac5b1623076620190", "target_scope": "Aurinia Pharmaceuticals Inc. (AUPH) is scheduled to release its Q2'26 earnings on July 30th.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.4, "provider_directional_mass": 0.2744, "relevance_score": 1.0, "company_focus": 0.86, "company_focus_pct": 86, "company_focus_label": "Company discussed", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.004041, "evidence_share": 0.4, "evidence_share_display": "0.4", "freshness_pct": 5.0, "age_days": 21.7, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Liquidity Mapping Around (AUPH) Price Events", "summary": "Aurinia Pharmaceuticals Inc (AUPH) is showing weak near and mid-term sentiment, despite a strong long-term outlook. The stock is currently testing support, and if it holds, resistance is expected next, with an exceptional risk-reward setup targeting an 11.4% gain. The article outlines different AI-generated trading strategies for various risk profiles, including position, momentum breakout, and risk hedging strategies.", "url": "https://news.stocktradersdaily.com/news_release/17/Liquidity_Mapping_Around_AUPH_Price_Events_072326094802_1784814482.html", "source_link": "https://news.stocktradersdaily.com/news_release/17/Liquidity_Mapping_Around_AUPH_Price_Events_072326094802_1784814482.html", "source_link_is_lookup": false, "source_name": "Stock Traders Daily", "published_at": "2026-07-23T10:10:40", "published_display": "23 Jul 2026 10:10", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["AUPH"], "target_provider_symbol": "AUPH", "cross_listing": false, "source_names": ["Stock Traders Daily"], "source_kind": "publisher", "story_key": "207d964eb92502cb7933c33211e0167f1859a687a2a5c670e03101e0af193f11", "target_scope": "Liquidity Mapping Around (AUPH) Price Events Aurinia Pharmaceuticals Inc (AUPH) is showing weak near and mid-term sentiment, despite a strong long-term outlook.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.452, "provider_directional_mass": 0.1016, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.4, "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.018559, "evidence_share": 2.1, "evidence_share_display": "2.1", "freshness_pct": 11.7, "age_days": 21.7, "influence_label": "Low", "duplicate_count": 1, "topics": ["Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharmaceuticals Inc (AUPH) Earnings, Actual EPS, EPS Estimates & Results", "summary": "This article provides an overview of Aurinia Pharmaceuticals Inc.'s (AUPH) earnings data, including upcoming and historical EPS and revenue reports. It highlights past earning beats and lists recent news and trending discussions related to the company. The company's next earnings report for Q2 '26 is estimated for July 30, with an estimated EPS of $0.24 and revenue of $80.45 million.", "url": "https://stocktwits.com/symbol/AUPH/earnings", "source_link": "https://stocktwits.com/symbol/AUPH/earnings", "source_link_is_lookup": false, "source_name": "Stocktwits", "published_at": "2026-07-23T01:10:40", "published_display": "23 Jul 2026 01:10", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["AUPH"], "target_provider_symbol": "AUPH", "cross_listing": false, "source_names": ["Stocktwits"], "source_kind": "publisher", "story_key": "8a4ea03fbf8ea9427620ccfd48312106ec0ae358a2f0fbc901b7b9cdf5f7d9b5", "target_scope": "Aurinia Pharmaceuticals Inc (AUPH) Earnings, Actual EPS, EPS Estimates & Results This article provides an overview of Aurinia Pharmaceuticals Inc.'s (AUPH) earnings data, including upcoming and historical EPS and revenue reports.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.461, "provider_directional_mass": 0.2599, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.006236, "evidence_share": 0.7, "evidence_share_display": "0.7", "freshness_pct": 4.7, "age_days": 22.1, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharmaceuticals Inc (AUPH) Fundamental & Financial Data", "summary": "This article provides fundamental and financial data for Aurinia Pharmaceuticals Inc (AUPH), including its current stock price, market capitalization, P/E ratio, and 52-week high/low. It also lists recent news regarding the company, such as its upgrade to \"Strong Buy\" by Zacks and the initiation of a new study for its drug LUPKYNIS in lupus nephritis patients. The page also shows trending tickers and community discussions related to other stocks.", "url": "https://stocktwits.com/symbol/AUPH/fundamentals", "source_link": "https://stocktwits.com/symbol/AUPH/fundamentals", "source_link_is_lookup": false, "source_name": "Stocktwits", "published_at": "2026-07-22T17:40:30", "published_display": "22 Jul 2026 17:40", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["AUPH"], "target_provider_symbol": "AUPH", "cross_listing": false, "source_names": ["Stocktwits"], "source_kind": "publisher", "story_key": "d2dce084140307cb6d1649cdc78a4f1820449fcc42f07f9a2f757b76eb37edf1", "target_scope": "Aurinia Pharmaceuticals Inc (AUPH) Fundamental & Financial Data This article provides fundamental and financial data for Aurinia Pharmaceuticals Inc (AUPH), including its current stock price, market capitalization, P/E ratio, and 52-week high/low.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.57, "provider_directional_mass": 0.0258, "relevance_score": 0.72, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 69, "tone_signals": ["Analyst upgrade"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.007943, "evidence_share": 0.9, "evidence_share_display": "0.9", "freshness_pct": 4.5, "age_days": 22.4, "influence_label": "Low", "duplicate_count": 1, "topics": ["Earnings", "Life Sciences", "Financial Markets"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharmaceuticals (AUPH) Q1 2026 earnings summary", "summary": "Aurinia Pharmaceuticals reported strong Q1 2026 results, with total revenue increasing 24% year-over-year to $77.7 million, driven by higher LUPKYNIS sales. Net income surged 48% to $34.4 million, and operating cash flows significantly improved. The company also saw significant management changes and provided positive full-year 2026 guidance.", "url": "https://quartr.com/events/aurinia-pharmaceuticals-inc-auph-q1-2026_3sQHoEI2", "source_link": "https://quartr.com/events/aurinia-pharmaceuticals-inc-auph-q1-2026_3sQHoEI2", "source_link_is_lookup": false, "source_name": "Quartr", "published_at": "2026-07-19T15:41:20", "published_display": "19 Jul 2026 15:41", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["AUPH", "AUPH.ARCHIVE"], "target_provider_symbol": "AUPH", "cross_listing": false, "source_names": ["Quartr"], "source_kind": "publisher", "story_key": "cdf7e626f710a4315c4f7d617647f910180b2e627d693b8e9a35ee669b2bf83f", "target_scope": "Aurinia Pharmaceuticals (AUPH) Q1 2026 earnings summary Aurinia Pharmaceuticals reported strong Q1 2026 results, with total revenue increasing 24% year-over-year to $77.7 million, driven by higher LUPKYNIS sales.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.621, "provider_directional_mass": 0.4134, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 76, "tone_signals": ["Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.007724, "evidence_share": 0.9, "evidence_share_display": "0.9", "freshness_pct": 2.9, "age_days": 25.5, "influence_label": "Low", "duplicate_count": 4, "topics": ["Earnings", "Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharmaceuticals (AUPH) Proxy Filing Summary", "summary": "Aurinia Pharmaceuticals (AUPH) released a proxy filing summary detailing strong 2024 LUPKYNIS sales, cash flow, and share repurchases. Shareholders will vote on directors, auditor appointment, a non-binding say-on-pay, and an amendment to the Equity Incentive Plan. The company also highlighted its updated corporate governance, including a reduced board size and independent committees.", "url": "https://quartr.com/events/aurinia-pharmaceuticals-auph-proxy-filing_3sQHXno5", "source_link": "https://quartr.com/events/aurinia-pharmaceuticals-auph-proxy-filing_3sQHXno5", "source_link_is_lookup": false, "source_name": "Quartr", "published_at": "2026-07-19T14:41:00", "published_display": "19 Jul 2026 14:41", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["AUPH"], "target_provider_symbol": "AUPH", "cross_listing": false, "source_names": ["Quartr"], "source_kind": "publisher", "story_key": "8fc19a66536d65deb1aa6485340f12e4bd09e9d4ea2090b8bb4792b1195c34f1", "target_scope": "Aurinia Pharmaceuticals (AUPH) Proxy Filing Summary Aurinia Pharmaceuticals (AUPH) released a proxy filing summary detailing strong 2024 LUPKYNIS sales, cash flow, and share repurchases.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.559, "provider_directional_mass": 0.4021, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 66, "tone_signals": ["Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.005719, "evidence_share": 0.6, "evidence_share_display": "0.6", "freshness_pct": 2.9, "age_days": 25.5, "influence_label": "Low", "duplicate_count": 3, "topics": ["Earnings", "Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Aurinia Pharmaceuticals (AUPH) Jefferies 2024 Global Healthcare Conference Summary", "summary": "Aurinia Pharmaceuticals presented a summary of its performance and outlook at the Jefferies 2024 Global Healthcare Conference. The company reported strong LUPKYNIS revenue growth, projecting to be cash flow positive in Q2, and highlighted efforts in market development, patient engagement, and product differentiation. Aurinia Pharmaceuticals detailed the drug's clinical benefits, market expansion plans, and financial health, emphasizing its significant cash reserves and non-dilutive capital from the Otsuka partnership.", "url": "https://quartr.com/events/aurinia-pharmaceuticals-inc-auph-jefferies-2024-global-healthcare-conference_3sQHujQp", "source_link": "https://quartr.com/events/aurinia-pharmaceuticals-inc-auph-jefferies-2024-global-healthcare-conference_3sQHujQp", "source_link_is_lookup": false, "source_name": "Quartr", "published_at": "2026-07-18T06:10:47", "published_display": "18 Jul 2026 06:10", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["AUPH", "AUPH.ARCHIVE"], "target_provider_symbol": "AUPH", "cross_listing": false, "source_names": ["Quartr"], "source_kind": "publisher", "story_key": "73e013bbd5a633c632b5bb2b18ba51277914fa114cb2e956f3f11907b8f4a2c5", "target_scope": "Aurinia Pharmaceuticals (AUPH) Jefferies 2024 Global Healthcare Conference Summary Aurinia Pharmaceuticals presented a summary of its performance and outlook at the Jefferies 2024 Global Healthcare Conference. Aurinia Pharmaceuticals detailed the drug's clinical benefits, market expansion plans, and financial health, emphasizing its significant cash reserves and non-dilutive capital from the Otsuka partnership.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "stored_reclassified", "model_confidence": 0.591, "provider_directional_mass": 0.4801, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.614, "sentiment": "neutral", "sentiment_pct": 55, "tone_signals": ["Operating growth", "Dilution risk"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.003962, "evidence_share": 0.4, "evidence_share_display": "0.4", "freshness_pct": 2.4, "age_days": 26.9, "influence_label": "Low", "duplicate_count": 2, "topics": ["Earnings", "Finance", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true}, {"title": "Crinetics Pharmaceuticals (CRNX) Stock Looks Fully Valued While Returns Stay Very Strong", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Crinetics+Pharmaceuticals+%28CRNX%29+Stock+Looks+Fully+Valued+While+Returns+Stay+Very+Strong%22+%22simplywall.st%22", "source_link_is_lookup": true, "source_name": "simplywall.st", "published_at": "2026-07-17T17:44:25.256245+00:00", "published_display": "17 Jul 2026 17:44", "provider": "archive", "providers": ["archive"], "provider_symbol": "", "provider_symbols": ["AUPH.ARCHIVE"], "target_provider_symbol": "AUPH.ARCHIVE", "cross_listing": false, "source_names": ["simplywall.st"], "source_kind": "publisher", "story_key": "85b7bf13b9aecfbd8a3c075351c58de3a33d0045aee07a41528b666dc04d253b", "target_scope": "Crinetics Pharmaceuticals (CRNX) Stock Looks Fully Valued While Returns Stay Very Strong", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "stored_reclassified", "model_confidence": 0.47, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 60, "tone_signals": ["Positive financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 6e-06, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.0, "age_days": 27.4, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}], "industry": [], "sector": []}, "total_fetched": 27, "total_unique": 27, "total_relevant": 27, "pipeline_health": {"eodhd": {"status": "healthy", "calls_used": 615, "configured": true, "last_error": "", "rate_limit": 1200, "call_budget": 10000, "requests_made": 123, "newest_seen_at": "2026-08-13T22:27:56+00:00", "rate_remaining": 1199, "budget_used_pct": 6.2, "last_success_at": "2026-08-13T22:36:10.458448+00:00", "mapped_mentions": 4056, "unmapped_mentions": 1866}, "status": "partial", "raw_articles": 46, "eodhd_articles": 0, "unique_stories": 27, "direct_evidence": 27, "provider_counts": {"eodhd": 0, "alphavantage": 38}, "provider_errors": {}, "archive_articles": 1, "current_evidence": 27, "relevant_stories": 27, "duplicates_removed": 19, "durable_story_count": 27, "providers_attempted": 2, "durable_collected_at": "2026-08-13T22:38:25.918535+00:00", "durable_evidence_used": true, "providers_with_results": 1, "matched_archive_stories": 27, "provider_rejected_counts": {"eodhd": 0, "alphavantage": 12}, "provider_relevant_counts": {"eodhd": 0, "alphavantage": 26}, "durable_newest_article_at": "2026-08-09T19:40:36+00:00"}, "sentiment_summary": {"positive": 13, "negative": 2, "neutral": 12, "score": 54, "raw_score": 57, "total": 27, "evidence_count": 27, "effective_articles": 12.2, "information_mass": 0.901, "direct_story_count": 27, "direct_source_count": 12, "industry_story_count": 0, "sector_story_count": 0, "story_count": 27, "source_count": 12, "source_concentration": 0.2255, "direct_share": 97, "dispersion": 20, "confidence": 34, "evidence_status": "measured", "score_version": "evidence-v9", "window_days": 30, "weighting_method": "event-aware exponential freshness decay", "newest_article_at": "2026-08-09T19:40:36+00:00", "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 86, "events": [{"event": "earnings", "label": "Earnings", "weight": 12.22, "count": 20}, {"event": "general", "label": "Market update", "weight": 1.8, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 1.2, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.6, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.6, "count": 1}], "positive_events": 13, "negative_events": 2, "pipeline": {"eodhd": {"status": "healthy", "calls_used": 615, "configured": true, "last_error": "", "rate_limit": 1200, "call_budget": 10000, "requests_made": 123, "newest_seen_at": "2026-08-13T22:27:56+00:00", "rate_remaining": 1199, "budget_used_pct": 6.2, "last_success_at": "2026-08-13T22:36:10.458448+00:00", "mapped_mentions": 4056, "unmapped_mentions": 1866}, "status": "partial", "raw_articles": 46, "eodhd_articles": 0, "unique_stories": 27, "direct_evidence": 27, "provider_counts": {"eodhd": 0, "alphavantage": 38}, "provider_errors": {}, "archive_articles": 1, "current_evidence": 27, "relevant_stories": 27, "duplicates_removed": 19, "durable_story_count": 27, "providers_attempted": 2, "durable_collected_at": "2026-08-13T22:38:25.918535+00:00", "durable_evidence_used": true, "providers_with_results": 1, "matched_archive_stories": 27, "provider_rejected_counts": {"eodhd": 0, "alphavantage": 12}, "provider_relevant_counts": {"eodhd": 0, "alphavantage": 26}, "durable_newest_article_at": "2026-08-09T19:40:36+00:00"}}, "market_context": {"has_market_context": true, "latest_close": 15.85, "latest_week": "2026-08-07", "one_week_move": 6.5, "four_week_move": 0.4, "twelve_week_move": 3.7, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.868417, "market_dynamics_buy_signal": false, "relative_strength": -4.863354, "fair_value_gap": 60.6, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 53.2795, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+6.5% over one week, +0.4% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 47, "badges": [], "opportunities": [], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 6}, {"label": "TradingKey", "count": 5}, {"label": "MarketBeat", "count": 3}, {"label": "Quartr", "count": 3}, {"label": "Stock Traders Daily", "count": 2}, {"label": "Stocktwits", "count": 2}, {"label": "Simply Wall St", "count": 1}, {"label": "BioSpace", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 27}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 20}, {"label": "Market update", "count": 3}, {"label": "Guidance", "count": 2}, {"label": "Analyst action", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Evidence confidence", "value": "34/100", "tone": "neutral", "text": "12.2 effective stories after overlap and weighting."}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "86/100 evidence concentration around this catalyst."}, {"label": "Company focus", "value": "27", "tone": "positive", "text": "97% of weighted evidence is company-specific."}, {"label": "Evidence agreement", "value": "20/100", "tone": "neutral", "text": "lower dispersion means the independent stories agree more closely."}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+6.5% over one week, +0.4% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Consensus Recommendation of \"Hold\" from Brokerages"}], "updated_at": "2026-08-13T22:38:25.918535+00:00", "detail_intelligence": {"headline": "Balanced news tone", "summary": "The score uses 27 current company stories from 12 publishers.", "status": "measured", "metrics": [{"label": "News score", "value": 54, "display": "54", "tone": "neutral", "note": "Balanced news tone"}, {"label": "Confidence", "value": 34, "display": "34", "tone": "negative", "note": "thin evidence"}, {"label": "Company news", "value": 97, "display": "97%", "tone": "positive", "note": "27 company stories"}, {"label": "Story agreement", "value": 80, "display": "80", "tone": "positive", "note": "20/100 difference"}], "confidence_drivers": [{"label": "Amount of evidence", "value": 18, "note": "0.901 after freshness weighting"}, {"label": "Source breadth", "value": 100, "note": "12 independent publishers"}, {"label": "Company relevance", "value": 97, "note": "share tied directly to this company"}, {"label": "Freshness", "value": 26, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 80, "note": "how closely stories agree"}, {"label": "Publisher mix", "value": 77, "note": "less reliance on one publisher"}], "freshness": 26, "source_independence": 77, "timeline": [{"date": "2026-07-16", "label": "16 Jul", "count": 0, "score": null, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-17", "label": "17 Jul", "count": 1, "score": 60, "tone": "positive", "x": 73.6, "y": 116.8, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-07-18", "label": "18 Jul", "count": 1, "score": 55, "tone": "neutral", "x": 105.2, "y": 125.9, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-07-19", "label": "19 Jul", "count": 2, "score": 72, "tone": "positive", "x": 136.8, "y": 95.0, "volume_height": 14.9, "volume_y": 251.1}, {"date": "2026-07-20", "label": "20 Jul", "count": 0, "score": null, "tone": "neutral", "x": 168.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-21", "label": "21 Jul", "count": 0, "score": null, "tone": "neutral", "x": 199.9, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-22", "label": "22 Jul", "count": 1, "score": 69, "tone": "positive", "x": 231.5, "y": 100.4, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-07-23", "label": "23 Jul", "count": 3, "score": 56, "tone": "neutral", "x": 263.1, "y": 124.1, "volume_height": 22.3, "volume_y": 243.7}, {"date": "2026-07-24", "label": "24 Jul", "count": 2, "score": 55, "tone": "neutral", "x": 294.7, "y": 125.9, "volume_height": 14.9, "volume_y": 251.1}, {"date": "2026-07-25", "label": "25 Jul", "count": 0, "score": null, "tone": "neutral", "x": 326.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-26", "label": "26 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 357.9, "y": 135.0, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-07-27", "label": "27 Jul", "count": 0, "score": null, "tone": "neutral", "x": 389.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-28", "label": "28 Jul", "count": 0, "score": null, "tone": "neutral", "x": 421.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-29", "label": "29 Jul", "count": 2, "score": 47, "tone": "neutral", "x": 452.6, "y": 140.5, "volume_height": 14.9, "volume_y": 251.1}, {"date": "2026-07-30", "label": "30 Jul", "count": 2, "score": 50, "tone": "neutral", "x": 484.2, "y": 135.0, "volume_height": 14.9, "volume_y": 251.1}, {"date": "2026-07-31", "label": "31 Jul", "count": 0, "score": null, "tone": "neutral", "x": 515.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-01", "label": "01 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 547.4, "y": 135.0, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-08-02", "label": "02 Aug", "count": 0, "score": null, "tone": "neutral", "x": 579.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-03", "label": "03 Aug", "count": 0, "score": null, "tone": "neutral", "x": 610.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-04", "label": "04 Aug", "count": 1, "score": 55, "tone": "neutral", "x": 642.1, "y": 125.9, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-08-05", "label": "05 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 673.7, "y": 135.0, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-08-06", "label": "06 Aug", "count": 7, "score": 56, "tone": "neutral", "x": 705.3, "y": 124.1, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-08-07", "label": "07 Aug", "count": 0, "score": null, "tone": "neutral", "x": 736.9, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-08", "label": "08 Aug", "count": 1, "score": 66, "tone": "positive", "x": 768.5, "y": 105.9, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-08-09", "label": "09 Aug", "count": 1, "score": 66, "tone": "positive", "x": 800.1, "y": 105.9, "volume_height": 7.4, "volume_y": 258.6}, {"date": "2026-08-10", "label": "10 Aug", "count": 0, "score": null, "tone": "neutral", "x": 831.7, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-11", "label": "11 Aug", "count": 0, "score": null, "tone": "neutral", "x": 863.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-12", "label": "12 Aug", "count": 0, "score": null, "tone": "neutral", "x": 894.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-13", "label": "13 Aug", "count": 0, "score": null, "tone": "neutral", "x": 926.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-14", "label": "14 Aug", "count": 0, "score": null, "tone": "neutral", "x": 958.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}], "timeline_points": "73.6,116.8 105.2,125.9 136.8,95.0 231.5,100.4 263.1,124.1 294.7,125.9 357.9,135.0 452.6,140.5 484.2,135.0 547.4,135.0 642.1,125.9 673.7,135.0 705.3,124.1 768.5,105.9 800.1,105.9", "timeline_has_signal": true, "timeline_start": "16 Jul", "timeline_mid": "31 Jul", "timeline_end": "14 Aug", "momentum": {"label": "Cooling", "tone": "neutral", "recent_score": null, "prior_score": 66, "delta": null, "recent_count": 0, "prior_count": 2, "volume_delta": -2, "reliable": false, "reliability_note": "Thin comparison; direction is not yet confirmed"}, "early_change": {"label": "No new story in 24 hours", "tone": "neutral", "latest_score": null, "baseline_score": 66, "delta": null, "latest_count": 0, "baseline_count": 2, "confirmed": false, "note": "A comparison needs current and earlier-week company news"}, "freshness_buckets": [{"label": "Last 24 hours", "count": 0, "share": 0}, {"label": "1 to 3 days", "count": 0, "share": 0}, {"label": "4 to 7 days", "count": 2, "share": 7}, {"label": "8 to 14 days", "count": 10, "share": 37}, {"label": "15 to 21 days", "count": 7, "share": 26}, {"label": "22 to 30 days", "count": 8, "share": 30}], "source_profile": [{"label": "TradingView", "count": 6, "share": 22, "score": 74, "tone": "positive"}, {"label": "TradingKey", "count": 5, "share": 19, "score": 49, "tone": "neutral"}, {"label": "Quartr", "count": 3, "share": 11, "score": 68, "tone": "positive"}, {"label": "MarketBeat", "count": 3, "share": 11, "score": 42, "tone": "negative"}, {"label": "Stocktwits", "count": 2, "share": 7, "score": 64, "tone": "positive"}, {"label": "Stock Traders Daily", "count": 2, "share": 7, "score": 56, "tone": "neutral"}, {"label": "simplywall.st", "count": 1, "share": 4, "score": 60, "tone": "positive"}], "event_profile": [{"label": "Earnings", "count": 20, "share": 74, "score": 57, "tone": "neutral"}, {"label": "Market update", "count": 3, "share": 11, "score": 50, "tone": "neutral"}, {"label": "Guidance", "count": 2, "share": 7, "score": 56, "tone": "neutral"}, {"label": "Analyst action", "count": 1, "share": 4, "score": 66, "tone": "positive"}, {"label": "Balance sheet", "count": 1, "share": 4, "score": 50, "tone": "neutral"}], "topics": [{"label": "Life Sciences", "count": 26, "share": 96}, {"label": "Earnings", "count": 21, "share": 78}, {"label": "Financial Markets", "count": 13, "share": 48}, {"label": "Finance", "count": 7, "share": 26}], "supporting": [{"label": "Direct evidence", "text": "27 current stories are mapped specifically to AUPH."}, {"label": "Source breadth", "text": "The score uses 12 publishers rather than depending on one outlet."}, {"label": "Story agreement", "text": "The current stories agree at 80/100."}], "tempering": [{"label": "Price disagreement", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Confidence", "text": "Confidence is 34/100, below the threshold for a firm score."}], "supporting_heading": "What supports the score", "tempering_heading": "What limits the score", "latest_observation": {"title": "Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Consensus Recommendation of \"Hold\" from Brokerages", "summary": "Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has received a consensus \"Hold\" rating from six brokerages, with an average 12-month price target of $17.67. This comes despite its CEO and other insiders acquiring a significant number of shares recently. The company beat EPS estimates but missed revenue forecasts in its latest quarterly report.", "url": "https://www.marketbeat.com/instant-alerts/aurinia-pharmaceuticals-inc-nasdaqauph-receives-consensus-recommendation-of-hold-from-brokerages-2026-08-09", "source_link": "https://www.marketbeat.com/instant-alerts/aurinia-pharmaceuticals-inc-nasdaqauph-receives-consensus-recommendation-of-hold-from-brokerages-2026-08-09", "source_link_is_lookup": false, "source_name": "MarketBeat", "published_at": "2026-08-09T19:40:36", "published_display": "09 Aug 2026 19:40", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "positive", "sentiment_pct": 66, "tone_signals": ["Beat expectations"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.059143, "evidence_share": 6.6, "evidence_share_display": "6.6", "freshness_pct": 37.0, "age_days": 4.3, "influence_label": "Low", "duplicate_count": 1, "topics": ["Life Sciences", "Earnings", "Financial Markets"], "evidence_basis": "archived_article", "score_included": true}, "article_count": 27, "updated_at": "2026-08-13T22:38:25.918535+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 191.5, "label": "13 Feb 2026", "close": 14.23, "index": 100.0}, {"x": 78.4, "y": 183.8, "label": "20 Feb 2026", "close": 14.4, "index": 101.2}, {"x": 114.9, "y": 194.2, "label": "27 Feb 2026", "close": 14.17, "index": 99.6}, {"x": 151.3, "y": 187.5, "label": "06 Mar 2026", "close": 14.32, "index": 100.6}, {"x": 187.7, "y": 204.2, "label": "13 Mar 2026", "close": 13.95, "index": 98.0}, {"x": 224.2, "y": 201.0, "label": "20 Mar 2026", "close": 14.02, "index": 98.5}, {"x": 260.6, "y": 189.7, "label": "27 Mar 2026", "close": 14.27, "index": 100.3}, {"x": 297.0, "y": 129.1, "label": "03 Apr 2026", "close": 15.61, "index": 109.7}, {"x": 333.5, "y": 122.3, "label": "10 Apr 2026", "close": 15.76, "index": 110.8}, {"x": 369.9, "y": 109.2, "label": "17 Apr 2026", "close": 16.05, "index": 112.8}, {"x": 406.3, "y": 112.4, "label": "24 Apr 2026", "close": 15.98, "index": 112.3}, {"x": 442.8, "y": 140.9, "label": "01 May 2026", "close": 15.35, "index": 107.9}, {"x": 479.2, "y": 146.3, "label": "08 May 2026", "close": 15.23, "index": 107.0}, {"x": 515.6, "y": 144.0, "label": "15 May 2026", "close": 15.28, "index": 107.4}, {"x": 552.0, "y": 146.7, "label": "22 May 2026", "close": 15.22, "index": 107.0}, {"x": 588.5, "y": 141.8, "label": "29 May 2026", "close": 15.33, "index": 107.7}, {"x": 624.9, "y": 118.7, "label": "05 Jun 2026", "close": 15.84, "index": 111.3}, {"x": 661.3, "y": 119.6, "label": "12 Jun 2026", "close": 15.82, "index": 111.2}, {"x": 697.8, "y": 90.6, "label": "19 Jun 2026", "close": 16.46, "index": 115.7}, {"x": 734.2, "y": 55.8, "label": "26 Jun 2026", "close": 17.23, "index": 121.1}, {"x": 770.6, "y": 129.1, "label": "03 Jul 2026", "close": 15.61, "index": 109.7}, {"x": 807.1, "y": 121.4, "label": "10 Jul 2026", "close": 15.78, "index": 110.9}, {"x": 843.5, "y": 113.3, "label": "17 Jul 2026", "close": 15.96, "index": 112.2}, {"x": 879.9, "y": 140.9, "label": "24 Jul 2026", "close": 15.35, "index": 107.9}, {"x": 916.4, "y": 162.1, "label": "31 Jul 2026", "close": 14.88, "index": 104.6}, {"x": 952.8, "y": 118.2, "label": "07 Aug 2026", "close": 15.85, "index": 111.4}], "sentiment_points": [{"at": "2026-06-26T23:59:59.999Z", "date": "2026-06-26", "label": "26 Jun 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 21, "stories": 3, "close": 17.23, "price_change": 4.7, "x": 739.4, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-03T23:59:59.999Z", "date": "2026-07-03", "label": "03 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 26, "stories": 7, "close": 15.61, "price_change": -9.4, "x": 775.8, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-10T23:59:59.999Z", "date": "2026-07-10", "label": "10 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 53, "confidence": 18, "stories": 8, "close": 15.78, "price_change": 1.1, "x": 812.3, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "label": "17 Jul 2026", "score": 51, "tone": "neutral", "raw_score": 55, "confidence": 26, "stories": 11, "close": 15.96, "price_change": 1.1, "x": 848.7, "y": 128.2, "show_label": true, "label_y": 118.19999999999999}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "label": "24 Jul 2026", "score": 54, "tone": "neutral", "raw_score": 59, "confidence": 38, "stories": 19, "close": 15.35, "price_change": -3.8, "x": 885.1, "y": 122.6, "show_label": true, "label_y": 112.6}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "label": "31 Jul 2026", "score": 52, "tone": "neutral", "raw_score": 54, "confidence": 32, "stories": 22, "close": 14.88, "price_change": -3.1, "x": 921.6, "y": 126.3, "show_label": true, "label_y": 116.3}, {"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "label": "07 Aug 2026", "score": 54, "tone": "neutral", "raw_score": 57, "confidence": 46, "stories": 29, "close": 15.85, "price_change": 6.5, "x": 958.0, "y": 122.6, "show_label": true, "label_y": 112.6}], "price_path": "42.0,191.5 78.4,183.8 114.9,194.2 151.3,187.5 187.7,204.2 224.2,201.0 260.6,189.7 297.0,129.1 333.5,122.3 369.9,109.2 406.3,112.4 442.8,140.9 479.2,146.3 515.6,144.0 552.0,146.7 588.5,141.8 624.9,118.7 661.3,119.6 697.8,90.6 734.2,55.8 770.6,129.1 807.1,121.4 843.5,113.3 879.9,140.9 916.4,162.1 952.8,118.2", "sentiment_path": "739.4,130.0 775.8,130.0 812.3,130.0 848.7,128.2 885.1,122.6 921.6,126.3 958.0,122.6", "score_version": "evidence-v9", "price_change": 11.4, "sentiment_change": 4, "recent_pairs": [{"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "label": "07 Aug 2026", "score": 54, "tone": "neutral", "raw_score": 57, "confidence": 46, "stories": 29, "close": 15.85, "price_change": 6.5, "x": 958.0, "y": 122.6, "show_label": true, "label_y": 112.6}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "label": "31 Jul 2026", "score": 52, "tone": "neutral", "raw_score": 54, "confidence": 32, "stories": 22, "close": 14.88, "price_change": -3.1, "x": 921.6, "y": 126.3, "show_label": true, "label_y": 116.3}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "label": "24 Jul 2026", "score": 54, "tone": "neutral", "raw_score": 59, "confidence": 38, "stories": 19, "close": 15.35, "price_change": -3.8, "x": 885.1, "y": 122.6, "show_label": true, "label_y": 112.6}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "label": "17 Jul 2026", "score": 51, "tone": "neutral", "raw_score": 55, "confidence": 26, "stories": 11, "close": 15.96, "price_change": 1.1, "x": 848.7, "y": 128.2, "show_label": true, "label_y": 118.19999999999999}, {"at": "2026-07-10T23:59:59.999Z", "date": "2026-07-10", "label": "10 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 53, "confidence": 18, "stories": 8, "close": 15.78, "price_change": 1.1, "x": 812.3, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-03T23:59:59.999Z", "date": "2026-07-03", "label": "03 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 26, "stories": 7, "close": 15.61, "price_change": -9.4, "x": 775.8, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-06-26T23:59:59.999Z", "date": "2026-06-26", "label": "26 Jun 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 21, "stories": 3, "close": 17.23, "price_change": 4.7, "x": 739.4, "y": 130.0, "show_label": true, "label_y": 120.0}], "reconstructed": true, "latest_close": 15.85, "start_label": "13 Feb", "mid_label": "15 May", "end_label": "07 Aug", "live_score_version": "evidence-v9", "comparable_to_live": true}, "sentiment_history": [{"label": "22 Jun 23:59", "short_label": "22 Jun", "collected_at": "2026-06-22T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": null, "score_change_display": "Start", "confidence_change": null, "article_change": null, "tone": "neutral", "height": 4, "articles": 1, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "23 Jun 23:59", "short_label": "23 Jun", "collected_at": "2026-06-23T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 2, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "25 Jun 23:59", "short_label": "25 Jun", "collected_at": "2026-06-25T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -4, "article_change": 1, "tone": "neutral", "height": 4, "articles": 3, "confidence": 23, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "29 Jun 23:59", "short_label": "29 Jun", "collected_at": "2026-06-29T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 5, "article_change": 1, "tone": "neutral", "height": 4, "articles": 4, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "30 Jun 23:59", "short_label": "30 Jun", "collected_at": "2026-06-30T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 5, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "02 Jul 23:59", "short_label": "02 Jul", "collected_at": "2026-07-02T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 6, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "03 Jul 23:59", "short_label": "03 Jul", "collected_at": "2026-07-03T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 7, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "04 Jul 23:59", "short_label": "04 Jul", "collected_at": "2026-07-04T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 1, "score_change_display": "+1", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 8, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "13 Jul 23:59", "short_label": "13 Jul", "collected_at": "2026-07-13T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -1, "score_change_display": "-1", "confidence_change": -4, "article_change": 1, "tone": "neutral", "height": 4, "articles": 9, "confidence": 22, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "14 Jul 23:59", "short_label": "14 Jul", "collected_at": "2026-07-14T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 4, "article_change": 1, "tone": "neutral", "height": 4, "articles": 10, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "17 Jul 23:59", "short_label": "17 Jul", "collected_at": "2026-07-17T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 1, "score_change_display": "+1", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 11, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "18 Jul 23:59", "short_label": "18 Jul", "collected_at": "2026-07-18T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": 3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 12, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "19 Jul 23:59", "short_label": "19 Jul", "collected_at": "2026-07-19T23:59:59.999999+00:00", "score": 56, "delta": 6, "score_change": 5, "score_change_display": "+5", "confidence_change": 7, "article_change": 2, "tone": "neutral", "height": 12, "articles": 14, "confidence": 36, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "22 Jul 23:59", "short_label": "22 Jul", "collected_at": "2026-07-22T23:59:59.999999+00:00", "score": 56, "delta": 6, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 0, "tone": "neutral", "height": 12, "articles": 14, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "23 Jul 23:59", "short_label": "23 Jul", "collected_at": "2026-07-23T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": -1, "score_change_display": "-1", "confidence_change": 4, "article_change": 3, "tone": "neutral", "height": 10, "articles": 17, "confidence": 37, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "24 Jul 23:59", "short_label": "24 Jul", "collected_at": "2026-07-24T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": -1, "score_change_display": "-1", "confidence_change": 1, "article_change": 2, "tone": "neutral", "height": 8, "articles": 19, "confidence": 38, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "26 Jul 23:59", "short_label": "26 Jul", "collected_at": "2026-07-26T23:59:59.999999+00:00", "score": 53, "delta": 3, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": 0, "tone": "neutral", "height": 6, "articles": 19, "confidence": 35, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "29 Jul 23:59", "short_label": "29 Jul", "collected_at": "2026-07-29T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": -1, "score_change_display": "-1", "confidence_change": -1, "article_change": 2, "tone": "neutral", "height": 4, "articles": 21, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "30 Jul 23:59", "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 22, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "01 Aug 23:59", "short_label": "01 Aug", "collected_at": "2026-08-01T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 0, "tone": "neutral", "height": 4, "articles": 22, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "04 Aug 23:59", "short_label": "04 Aug", "collected_at": "2026-08-04T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": -1, "article_change": -1, "tone": "neutral", "height": 4, "articles": 21, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "05 Aug 23:59", "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 22, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "06 Aug 23:59", "short_label": "06 Aug", "collected_at": "2026-08-06T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": 3, "score_change_display": "+3", "confidence_change": 20, "article_change": 7, "tone": "neutral", "height": 8, "articles": 29, "confidence": 49, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "08 Aug 23:59", "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": 1, "score_change_display": "+1", "confidence_change": -4, "article_change": 1, "tone": "neutral", "height": 10, "articles": 30, "confidence": 45, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "09 Aug 23:59", "short_label": "09 Aug", "collected_at": "2026-08-09T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 10, "articles": 31, "confidence": 44, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "14 Aug 03:04", "short_label": "14 Aug", "collected_at": "2026-08-14T03:04:48.787534+00:00", "score": 54, "delta": 4, "score_change": -1, "score_change_display": "-1", "confidence_change": -11, "article_change": -2, "tone": "neutral", "height": 8, "articles": 29, "confidence": 33, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}], "sentiment_history_insight": {"available": true, "series_version": "evidence-v9", "live_version": "evidence-v9", "comparable_to_live": true, "reconstructed": true, "observations": 26, "span_label": "52 days", "first_score": 50, "latest_score": 54, "net_change": 4, "net_change_display": "+4", "direction": "Strengthening", "high_score": 56, "low_score": 50, "latest_confidence": 33, "confidence_change": 5, "latest_articles": 29, "article_change": 28, "latest_label": "14 Aug 03:04", "latest_evidence_label": "Measured", "chart_rows": [{"label": "22 Jun 23:59", "short_label": "22 Jun", "collected_at": "2026-06-22T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": null, "score_change_display": "Start", "confidence_change": null, "article_change": null, "tone": "neutral", "height": 4, "articles": 1, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 42.0, "y": 135.0}, {"label": "23 Jun 23:59", "short_label": "23 Jun", "collected_at": "2026-06-23T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 2, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 78.6, "y": 135.0}, {"label": "25 Jun 23:59", "short_label": "25 Jun", "collected_at": "2026-06-25T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -4, "article_change": 1, "tone": "neutral", "height": 4, "articles": 3, "confidence": 23, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 115.3, "y": 135.0}, {"label": "29 Jun 23:59", "short_label": "29 Jun", "collected_at": "2026-06-29T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 5, "article_change": 1, "tone": "neutral", "height": 4, "articles": 4, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 151.9, "y": 135.0}, {"label": "30 Jun 23:59", "short_label": "30 Jun", "collected_at": "2026-06-30T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 5, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 188.6, "y": 135.0}, {"label": "02 Jul 23:59", "short_label": "02 Jul", "collected_at": "2026-07-02T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 6, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 225.2, "y": 135.0}, {"label": "03 Jul 23:59", "short_label": "03 Jul", "collected_at": "2026-07-03T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 7, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 261.8, "y": 135.0}, {"label": "04 Jul 23:59", "short_label": "04 Jul", "collected_at": "2026-07-04T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 1, "score_change_display": "+1", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 8, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 298.5, "y": 133.2}, {"label": "13 Jul 23:59", "short_label": "13 Jul", "collected_at": "2026-07-13T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -1, "score_change_display": "-1", "confidence_change": -4, "article_change": 1, "tone": "neutral", "height": 4, "articles": 9, "confidence": 22, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 335.1, "y": 135.0}, {"label": "14 Jul 23:59", "short_label": "14 Jul", "collected_at": "2026-07-14T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 4, "article_change": 1, "tone": "neutral", "height": 4, "articles": 10, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 371.8, "y": 135.0}, {"label": "17 Jul 23:59", "short_label": "17 Jul", "collected_at": "2026-07-17T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 1, "score_change_display": "+1", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 11, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 408.4, "y": 133.2}, {"label": "18 Jul 23:59", "short_label": "18 Jul", "collected_at": "2026-07-18T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": 3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 12, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 445.0, "y": 133.2}, {"label": "19 Jul 23:59", "short_label": "19 Jul", "collected_at": "2026-07-19T23:59:59.999999+00:00", "score": 56, "delta": 6, "score_change": 5, "score_change_display": "+5", "confidence_change": 7, "article_change": 2, "tone": "neutral", "height": 12, "articles": 14, "confidence": 36, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 481.7, "y": 124.1}, {"label": "22 Jul 23:59", "short_label": "22 Jul", "collected_at": "2026-07-22T23:59:59.999999+00:00", "score": 56, "delta": 6, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 0, "tone": "neutral", "height": 12, "articles": 14, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 518.3, "y": 124.1}, {"label": "23 Jul 23:59", "short_label": "23 Jul", "collected_at": "2026-07-23T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": -1, "score_change_display": "-1", "confidence_change": 4, "article_change": 3, "tone": "neutral", "height": 10, "articles": 17, "confidence": 37, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 555.0, "y": 125.9}, {"label": "24 Jul 23:59", "short_label": "24 Jul", "collected_at": "2026-07-24T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": -1, "score_change_display": "-1", "confidence_change": 1, "article_change": 2, "tone": "neutral", "height": 8, "articles": 19, "confidence": 38, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true, "x": 591.6, "y": 127.7}, {"label": "26 Jul 23:59", "short_label": "26 Jul", "collected_at": "2026-07-26T23:59:59.999999+00:00", "score": 53, "delta": 3, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": 0, "tone": "neutral", "height": 6, "articles": 19, "confidence": 35, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 628.2, "y": 129.5}, {"label": "29 Jul 23:59", "short_label": "29 Jul", "collected_at": "2026-07-29T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": -1, "score_change_display": "-1", "confidence_change": -1, "article_change": 2, "tone": "neutral", "height": 4, "articles": 21, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 664.9, "y": 131.4}, {"label": "30 Jul 23:59", "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 22, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 701.5, "y": 131.4}, {"label": "01 Aug 23:59", "short_label": "01 Aug", "collected_at": "2026-08-01T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 0, "tone": "neutral", "height": 4, "articles": 22, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 738.2, "y": 131.4}, {"label": "04 Aug 23:59", "short_label": "04 Aug", "collected_at": "2026-08-04T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": -1, "article_change": -1, "tone": "neutral", "height": 4, "articles": 21, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 774.8, "y": 133.2}, {"label": "05 Aug 23:59", "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 22, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true, "x": 811.4, "y": 133.2}, {"label": "06 Aug 23:59", "short_label": "06 Aug", "collected_at": "2026-08-06T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": 3, "score_change_display": "+3", "confidence_change": 20, "article_change": 7, "tone": "neutral", "height": 8, "articles": 29, "confidence": 49, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true, "x": 848.1, "y": 127.7}, {"label": "08 Aug 23:59", "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": 1, "score_change_display": "+1", "confidence_change": -4, "article_change": 1, "tone": "neutral", "height": 10, "articles": 30, "confidence": 45, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true, "x": 884.7, "y": 125.9}, {"label": "09 Aug 23:59", "short_label": "09 Aug", "collected_at": "2026-08-09T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 10, "articles": 31, "confidence": 44, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true, "x": 921.4, "y": 125.9}, {"label": "14 Aug 03:04", "short_label": "14 Aug", "collected_at": "2026-08-14T03:04:48.787534+00:00", "score": 54, "delta": 4, "score_change": -1, "score_change_display": "-1", "confidence_change": -11, "article_change": -2, "tone": "neutral", "height": 8, "articles": 29, "confidence": 33, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true, "x": 958.0, "y": 127.7}], "chart_points": "42.0,135.0 78.6,135.0 115.3,135.0 151.9,135.0 188.6,135.0 225.2,135.0 261.8,135.0 298.5,133.2 335.1,135.0 371.8,135.0 408.4,133.2 445.0,133.2 481.7,124.1 518.3,124.1 555.0,125.9 591.6,127.7 628.2,129.5 664.9,131.4 701.5,131.4 738.2,131.4 774.8,133.2 811.4,133.2 848.1,127.7 884.7,125.9 921.4,125.9 958.0,127.7", "changes": [{"label": "14 Aug 03:04", "short_label": "14 Aug", "collected_at": "2026-08-14T03:04:48.787534+00:00", "score": 54, "delta": 4, "score_change": -1, "score_change_display": "-1", "confidence_change": -11, "article_change": -2, "tone": "neutral", "height": 8, "articles": 29, "confidence": 33, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "09 Aug 23:59", "short_label": "09 Aug", "collected_at": "2026-08-09T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 10, "articles": 31, "confidence": 44, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "08 Aug 23:59", "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": 1, "score_change_display": "+1", "confidence_change": -4, "article_change": 1, "tone": "neutral", "height": 10, "articles": 30, "confidence": 45, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "06 Aug 23:59", "short_label": "06 Aug", "collected_at": "2026-08-06T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": 3, "score_change_display": "+3", "confidence_change": 20, "article_change": 7, "tone": "neutral", "height": 8, "articles": 29, "confidence": 49, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v9", "reconstructed": true}, {"label": "05 Aug 23:59", "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 22, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "04 Aug 23:59", "short_label": "04 Aug", "collected_at": "2026-08-04T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": -1, "article_change": -1, "tone": "neutral", "height": 4, "articles": 21, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "01 Aug 23:59", "short_label": "01 Aug", "collected_at": "2026-08-01T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 0, "tone": "neutral", "height": 4, "articles": 22, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}, {"label": "30 Jul 23:59", "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 22, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v9", "reconstructed": true}]}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}